Ex Vivo Adenoviral Vector-Mediated Neurotrophin Gene Transfer to Olfactory Ensheathing Glia : Effects on Rubrospinal Tract Regeneration , Lesion Size , and Functional Recovery after Implantation in the Injured Rat Spinal Cord Marc J. Ruitenberg ,1 * Giles W. Plant ,2,3 * Frank P. T. Hamers ,4 Joke Wortel ,1 Bas Blits ,1 Paul A. Dijkhuizen ,1 Willem Hendrik Gispen ,4 Gerard J. Boer ,1 and Joost Verhaagen1 1Graduate School for Neurosciences Amsterdam , Netherlands Institute for Brain Research , 1105 AZ , Amsterdam , The Netherlands , 2Red 's Spinal Cord Research Laboratory , School of Anatomy and Human Biology , Clinical Training and Education Center Building , and 3Western Australian Institute for Medical Research , The University of Western Australia , Crawley , Perth , WA 6009 , Australia , and 4Department of Anatomy and Pharmacology , Rudolf Magnus Institute for Neurosciences , 3584 CG , Utrecht , The Netherlands The present study	1
Ex Vivo Adenoviral Vector-Mediated Neurotrophin Gene Transfer to Olfactory Ensheathing Glia	1
Ex Vivo	1
Adenoviral Vector-Mediated Neurotrophin Gene Transfer to Olfactory Ensheathing Glia	9
Adenoviral Vector-Mediated Neurotrophin Gene Transfer	9
Olfactory Ensheathing Glia	66
Effects on Rubrospinal Tract Regeneration , Lesion Size , and Functional Recovery after Implantation in the Injured Rat Spinal Cord Marc J. Ruitenberg ,1 * Giles W. Plant ,2,3 * Frank P. T. Hamers ,4 Joke Wortel ,1 Bas Blits ,1 Paul A. Dijkhuizen ,1 Willem Hendrik Gispen ,4 Gerard J. Boer ,1 and Joost Verhaagen1 1Graduate School for Neurosciences Amsterdam	94
Effects on Rubrospinal Tract Regeneration , Lesion Size , and Functional Recovery after Implantation in the Injured Rat Spinal Cord Marc J. Ruitenberg ,1 * Giles W. Plant ,2,3 * Frank P. T. Hamers ,4 Joke Wortel ,1 Bas Blits ,1 Paul A. Dijkhuizen ,1 Willem Hendrik Gispen ,4 Gerard J. Boer ,1	94
Effects	94
Rubrospinal Tract Regeneration , Lesion Size , and Functional Recovery after Implantation in the Injured Rat Spinal Cord Marc J. Ruitenberg ,1 * Giles W. Plant ,2,3	105
Rubrospinal Tract Regeneration	105
Lesion Size	137
Functional Recovery after Implantation in the Injured Rat Spinal Cord Marc J. Ruitenberg ,1 * Giles W. Plant ,2,3	154
Functional Recovery after Implantation in the Injured Rat Spinal Cord Marc J. Ruitenberg ,1 *	154
Functional Recovery	154
Implantation in the Injured Rat Spinal Cord Marc J. Ruitenberg ,1	180
Implantation	180
the Injured Rat Spinal Cord Marc J. Ruitenberg ,1	196
Giles W. Plant ,2,3	247
Frank P. T. Hamers ,4 Joke Wortel ,1	267
Frank P. T. Hamers	267
,4 Joke Wortel ,1	285
Bas Blits ,1 Paul A.	302
Bas Blits	302
,1 Paul A.	311
Dijkhuizen ,1 Willem Hendrik Gispen ,4 Gerard J. Boer	322
Dijkhuizen ,1 Willem Hendrik	322
Gispen ,4 Gerard J. Boer	350
,1	373
Joost Verhaagen1 1Graduate School for Neurosciences Amsterdam	380
Joost Verhaagen1 1Graduate School	380
Neurosciences Amsterdam	418
Netherlands Institute for Brain Research	443
Netherlands Institute	443
Brain Research	469
1105 AZ , Amsterdam , The Netherlands	485
1105 AZ , Amsterdam	485
The Netherlands	505
2Red 's Spinal Cord Research Laboratory	522
2Red 's Spinal Cord	522
2Red 's	522
Research Laboratory	541
School of Anatomy and Human Biology	562
School	562
Anatomy and Human Biology	572
Anatomy	572
Human Biology	584
Clinical Training and Education Center Building	599
Clinical Training	599
Education Center Building	621
3Western Australian Institute for Medical Research , The University of Western Australia , Crawley , Perth , WA 6009 , Australia , and 4Department of Anatomy and Pharmacology , Rudolf Magnus Institute for Neurosciences , 3584 CG , Utrecht , The Netherlands The present study	652
3Western Australian Institute	652
Medical Research , The University of Western Australia , Crawley , Perth , WA 6009 , Australia , and 4Department of Anatomy and Pharmacology , Rudolf Magnus Institute for Neurosciences , 3584 CG , Utrecht , The Netherlands The present study	686
Medical Research , The University of Western Australia , Crawley , Perth , WA 6009 , Australia , and 4Department of Anatomy and Pharmacology	686
Medical Research	686
The University of Western Australia , Crawley , Perth , WA 6009 , Australia , and 4Department of Anatomy and Pharmacology	704
The University	704
Western Australia , Crawley , Perth , WA 6009 , Australia , and 4Department of Anatomy and Pharmacology	722
Western Australia , Crawley , Perth , WA 6009	722
Australia	766
4Department of Anatomy and Pharmacology	781
4Department	781
Anatomy and Pharmacology	796
Rudolf Magnus Institute for Neurosciences	822
Rudolf Magnus Institute	822
Neurosciences	850
3584 CG , Utrecht	865
The Netherlands The present study	883
The Netherlands	883
The present study	900
olfactory ensheathing glia -LRB- OEG -RRB- implantation with ex vivo adenoviral -LRB- AdV -RRB- vector-based neurotrophin gene therapy in an attempt to enhance regeneration after cervical spinal cord injury	936
olfactory ensheathing glia -LRB- OEG -RRB- implantation	936
ex vivo adenoviral	987
ex vivo	987
AdV	1007
vector-based neurotrophin gene therapy in an attempt to enhance regeneration after cervical spinal cord injury	1012
vector-based neurotrophin gene therapy	1012
an attempt to enhance regeneration after cervical spinal cord injury	1054
regeneration	1076
cervical spinal cord injury	1095
Primary OEG	1124
AdV vectors encoding rat brain-derived neurotrophic factor -LRB- BDNF -RRB- , neurotrophin-3 -LRB- NT-3 -RRB- , or bacterial marker protein betta-galactosidase -LRB- LacZ -RRB-	1157
AdV vectors encoding rat brain-derived neurotrophic factor -LRB- BDNF -RRB-	1157
AdV vectors	1157
rat brain-derived neurotrophic factor -LRB- BDNF -RRB-	1178
rat brain-derived neurotrophic factor	1178
BDNF	1217
neurotrophin-3 -LRB- NT-3 -RRB-	1224
neurotrophin-3	1224
NT-3	1240
bacterial marker protein betta-galactosidase -LRB- LacZ -RRB-	1250
bacterial marker protein betta-galactosidase	1250
LacZ	1296
adult Fischer rats	1334
unilateral transection of the dorsolateral funiculus	1368
unilateral transection	1368
the dorsolateral funiculus	1394
animals	1432
a total of 2x10 ^	1449
a total	1449
2x10 ^	1460
5 OEG that were subjected to transduction with neurotrophin-encoding AdV vector , AdV-LacZ , or no vector , respectively	1465
5 OEG	1465
transduction	1494
neurotrophin-encoding AdV vector , AdV-LacZ , or no vector	1512
neurotrophin-encoding AdV vector	1512
AdV-LacZ	1546
no vector	1559
4 months after injury	1587
4 months	1587
injury	1602
lesion volumes	1610
allOEGimplanted rats	1641
size	1691
implantation of neurotrophin-encoding AdV vector-transduced OEG	1702
implantation	1702
neurotrophin-encoding AdV vector-transduced OEG	1718
All OEG grafts	1767
neurofilament-positive axons	1799
AdV vector-mediated expression of BDNF by implanted cells	1833
AdV vector-mediated expression	1833
BDNF by implanted cells	1867
BDNF	1867
implanted cells	1875
the rubrospinal tract	1940
Behavioral analysis	1963
OEG-implanted rats	1997
better locomotion	2026
horizontal rope walking	2051
unimplanted lesioned controls	2080
Recovery of hind limb function	2111
Recovery	2111
hind limb function	2123
implantation of OEG that were transduced with a BDNF - or NT-3-encoding AdV vector	2166
implantation of OEG that were transduced with a BDNF	2166
implantation	2166
OEG	2182
a BDNF	2212
NT-3-encoding AdV vector	2223
Hind limb performance during horizontal rope locomotion	2249
Hind limb performance	2249
horizontal rope locomotion	2278
lesion size	2333
neuroprotective effects of OEG implants	2362
neuroprotective effects	2362
OEG implants	2389
the level of functional recovery	2417
the level	2417
functional recovery	2430
our results	2457
genetic engineering of OEG	2486
genetic engineering	2486
OEG	2509
a cell that was more effective in promoting axonal outgrowth	2534
a cell	2534
axonal outgrowth	2578
enhanced recovery after injury	2618
enhanced recovery	2618
injury	2642
sparing of spinal tissue	2662
sparing	2662
spinal tissue	2673
Introduction Impairment in voluntary motor function after spinal trauma	2689
Introduction Impairment	2689
voluntary motor function after spinal trauma	2716
voluntary motor function	2716
spinal trauma	2747
disruption of descending motor pathways at the injury site -LRB- Nathan , 1994 -RRB-	2790
disruption	2790
descending motor pathways at the injury site -LRB- Nathan , 1994 -RRB-	2804
descending motor pathways	2804
the injury site -LRB- Nathan , 1994 -RRB-	2833
the injury site	2833
Nathan	2850
1994	2858
such damage	2871
very little regenerative response	2884
a permanent loss of function and paralysis	2939
a permanent loss	2939
function and paralysis	2959
This paucity of regeneration in the adult mammalian CNS	2983
This paucity	2983
regeneration in the adult mammalian CNS	2999
regeneration	2999
the adult mammalian CNS	3015
a negative balance between factors that inhibit or promote axon growth -LRB- for review , see Schwab and Bartholdi , 1996 ; Fournier and Strittmatter , 2001 -RRB-	3063
a negative balance	3063
factors that inhibit or promote axon growth -LRB- for review , see Schwab and Bartholdi , 1996 ; Fournier and Strittmatter , 2001 -RRB-	3090
factors	3090
axon growth	3122
review	3139
Schwab and Bartholdi , 1996 ; Fournier and Strittmatter , 2001	3151
Schwab and Bartholdi , 1996	3151
Schwab and Bartholdi	3151
1996	3173
Fournier and Strittmatter , 2001	3179
Fournier and Strittmatter	3179
2001	3206
Neurotrophic factor delivery	3213
inhibition	3283
regeneration of spinal motor pathways , such as the corticospinal tract -LRB- CST -RRB- and rubrospinal tract -LRB- RST -RRB-	3306
regeneration	3306
spinal motor pathways	3322
the corticospinal tract -LRB- CST -RRB- and rubrospinal tract -LRB- RST -RRB-	3353
the corticospinal tract	3353
CST	3378
rubrospinal tract	3387
RST	3406
review	3416
Jones	3428
et al. , 2001 ; Murray and Fischer , 2001	3434
et al.	3434
2001 ; Murray and Fischer , 2001	3442
2001	3442
Murray and Fischer , 2001	3448
Murray and Fischer	3448
2001	3468
Neurotrophins	3475
their beneficial effects	3508
neuroprotection and neurite outgrowth	3536
Local delivery of neurotrophins	3575
Local delivery	3575
neurotrophins	3593
pathological events	3622
a regenerative response	3653
both acute -LRB- Schnell et al. , 1994 ; Tetzlaff et al. , 1994 -RRB- and chronic -LRB- Houle and Ye , 1999 ; Kwon et al. , 2002 -RRB- spinal cord injury	3683
Schnell et al. , 1994 ; Tetzlaff et al. , 1994 -RRB- and chronic -LRB- Houle and Ye , 1999 ; Kwon et al. , 2002	3695
Schnell	3695
et al. , 1994 ; Tetzlaff et al. , 1994 -RRB- and chronic -LRB- Houle and Ye , 1999 ; Kwon et al. , 2002	3703
et al. , 1994	3703
et al.	3703
1994	3711
Tetzlaff et al. , 1994 -RRB- and chronic -LRB- Houle and Ye , 1999	3717
Tetzlaff et al. , 1994 -RRB-	3717
Tetzlaff	3717
et al.	3726
1994	3734
chronic -LRB- Houle and Ye , 1999	3744
chronic	3744
Ye	3763
1999	3767
Kwon et al. , 2002	3773
Kwon	3773
et al. , 2002	3778
et al.	3778
2002	3786
addition to intraparenchymal infusions	3815
addition	3815
intraparenchymal infusions	3827
genetically modified cells that deliver neurotrophins	3855
genetically modified cells	3855
neurotrophins	3895
Engineered fibroblasts -LRB- Grill et al. , 1997 ; Liu et al. , 1999 -RRB- , Schwann cells -LRB- Menei et al. , 1998 -RRB- , and pieces of peripheral nerve -LRB- Blits et al. , 2000 -RRB-	3928
Engineered fibroblasts -LRB- Grill et al. , 1997 ; Liu et al. , 1999 -RRB- , Schwann cells -LRB- Menei et al. , 1998 -RRB- , and pieces of peripheral nerve	3928
Engineered fibroblasts -LRB- Grill et al. , 1997 ; Liu et al. , 1999 -RRB-	3928
Engineered fibroblasts	3928
Grill	3952
et al. , 1997 ; Liu et al. , 1999	3958
et al.	3958
1997 ; Liu et al.	3966
1997	3966
Liu et al.	3972
Liu	3972
et al.	3976
1999	3984
Schwann cells -LRB- Menei et al. , 1998 -RRB-	3991
Schwann cells	3991
Menei	4006
et al. , 1998	4012
et al.	4012
1998	4020
pieces of peripheral nerve	4031
pieces	4031
peripheral nerve	4041
Blits	4059
et al. , 2000	4065
et al.	4065
2000	4073
regeneration	4104
injury	4123
much research	4141
the use of olfactory ensheathing glia -LRB- OEG -RRB- that may have advantages over other cellular conduits -LRB- for review , see Franklin and Barnett , 2000 ; Plant et al. , 2000 -RRB-	4170
the use	4170
olfactory ensheathing glia -LRB- OEG -RRB- that may have advantages over other cellular conduits -LRB- for review , see Franklin and Barnett , 2000 ; Plant et al. , 2000 -RRB-	4181
olfactory ensheathing glia	4181
OEG	4209
advantages over other cellular conduits	4228
advantages	4228
other cellular conduits	4244
review	4273
Franklin and Barnett , 2000 ; Plant et al. , 2000	4285
Franklin and Barnett , 2000	4285
Franklin and Barnett	4285
2000	4307
Plant et al. , 2000	4313
Plant	4313
et al. , 2000	4319
et al.	4319
2000	4327
the adult olfactory neuroepithelium	4337
dying receptor neurons	4374
a compartment of stem cells	4415
a compartment	4415
stem cells	4432
the basal region of the epithelium -LRB- Farbman , 1992 -RRB-	4446
the basal region	4446
the epithelium -LRB- Farbman , 1992 -RRB-	4466
the epithelium	4466
Farbman	4482
1992	4491
The ability of new primary olfactory neurons to elongate their axons into a CNS environment	4498
The ability	4498
new primary olfactory neurons	4513
their axons	4555
a CNS environment	4572
the presence of OEG -LRB- Doucette , 1990 , 1991 -RRB-	4618
the presence	4618
OEG -LRB- Doucette , 1990 , 1991 -RRB-	4634
OEG	4634
Doucette	4639
1990	4649
1991	4655
These cells uniquely present both Schwann cell-like and astrocyte-like characteristics -LRB- for review ,	4662
These cells uniquely present	4662
These cells	4662
Schwann cell-like and astrocyte-like characteristics -LRB- for review ,	4696
Schwann	4696
cell-like and astrocyte-like characteristics -LRB- for review ,	4704
cell-like and astrocyte-like characteristics	4704
review	4754
Ramon-Cueto and Avila , 1998	4766
Ramon-Cueto and Avila	4766
1998	4789
great potential	4812
the damaged spinal cord -LRB- Li et al. , 1997 , 1998 ; Ramon-Cueto et al. , 1998 ; Barnett et al. , 2000 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2001a -RRB-	4838
the damaged spinal cord	4838
Li	4863
et al. , 1997 , 1998 ; Ramon-Cueto et al. , 1998 ; Barnett et al. , 2000 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2001a	4866
et al.	4866
1997 , 1998 ; Ramon-Cueto et al. , 1998 ; Barnett et al. , 2000 ; Ramon-Cueto et al. , 2000 ; Lu et al.	4874
1997 , 1998	4874
1997	4874
1998	4880
Ramon-Cueto et al. , 1998	4886
Ramon-Cueto	4886
et al. , 1998	4898
et al.	4898
1998	4906
Barnett et al. , 2000	4912
Barnett	4912
et al. , 2000	4920
et al.	4920
2000	4928
Ramon-Cueto et al. , 2000	4934
Ramon-Cueto	4934
et al. , 2000	4946
et al.	4946
2000	4954
Lu et al.	4960
Lu	4960
et al.	4963
2001a	4971
not all axonal populations	4988
OEG implants -LRB- Gudino-Cabrera et al. , 2000 -RRB-	5025
OEG implants	5025
Gudino-Cabrera	5039
et al. , 2000	5054
et al.	5054
2000	5062
Additional adenoviral	5069
AdV	5092
vector-mediated neurotrophin expression	5097
their regeneration-supporting properties , because endogenous neurotrophic factor expression by OEG is low -LRB- Boruch et al. , 2001 ; Woodhall et al. , 2001 -RRB-	5151
their regeneration-supporting properties , because endogenous neurotrophic factor expression by OEG is low	5151
their regeneration-supporting properties	5151
endogenous neurotrophic factor expression by OEG	5201
endogenous neurotrophic factor expression	5201
OEG	5246
Boruch	5258
et al. , 2001 ; Woodhall et al. , 2001	5265
et al.	5265
2001 ; Woodhall et al.	5273
2001	5273
Woodhall et al.	5279
Woodhall	5279
et al.	5288
2001	5296
AdVvector-mediated gene transfer to OEG results in transient transgene expression for ≈ 30 d after implantation in the lesioned rat spinal cord -LRB- Ruitenberg et al. , 2002 -RRB- .	5302
AdVvector-mediated gene transfer	5302
OEG results	5338
transient transgene expression for ≈ 30 d after implantation in the lesioned rat spinal cord -LRB- Ruitenberg et al. , 2002 -RRB-	5353
transient transgene expression	5353
≈ 30 d after implantation in the lesioned rat spinal cord -LRB- Ruitenberg et al. , 2002 -RRB-	5388
≈ 30 d after implantation in the lesioned rat spinal cord	5388
implantation in the lesioned rat	5400
implantation	5400
the lesioned rat	5416
Ruitenberg	5446
et al. , 2002	5457
et al.	5457
2002	5465
The present experiment	5472
a new approach	5506
spinal cord repair	5524
ex vivo AdV	5555
vector-transduced OEG implants in an attempt to create more conducive conditions for RST regeneration	5567
vector-transduced OEG implants	5567
an attempt to create more conducive conditions for RST regeneration	5601
more conducive conditions for RST regeneration	5622
more conducive conditions	5622
RST regeneration	5652
We	5670
the effects of AdV vector-mediated hypersecretion of brain-derived neurotrophic factor -LRB- BDNF -RRB- and neurotrophin-3 -LRB- NT-3 -RRB- , two putative RST neurotrophic factors -LRB- Kobayashi et al. , 1997 ; Liebl et al. , 2001 -RRB- ,	5682
the effects	5682
AdV vector-mediated hypersecretion of brain-derived neurotrophic factor -LRB- BDNF -RRB- and neurotrophin-3 -LRB- NT-3 -RRB- , two putative RST neurotrophic factors -LRB- Kobayashi et al. , 1997 ; Liebl et al. , 2001 -RRB- ,	5697
AdV vector-mediated hypersecretion of brain-derived neurotrophic factor -LRB- BDNF -RRB- and neurotrophin-3	5697
AdV vector-mediated hypersecretion	5697
brain-derived neurotrophic factor -LRB- BDNF -RRB- and neurotrophin-3	5735
brain-derived neurotrophic factor -LRB- BDNF -RRB-	5735
brain-derived neurotrophic factor	5735
BDNF	5770
neurotrophin-3	5780
NT-3	5796
two putative RST neurotrophic factors -LRB- Kobayashi et al. , 1997 ; Liebl et al. , 2001 -RRB-	5803
two putative RST neurotrophic factors	5803
Kobayashi	5842
et al. , 1997 ; Liebl et al. , 2001	5852
et al.	5852
1997 ; Liebl et al.	5860
1997	5860
Liebl et al.	5866
Liebl	5866
et al.	5872
2001	5880
functional recovery and RST regeneration	5890
cervical injury	5937
Anatomical , electrophysiological , and functional analysis	5954
Anatomical	5954
electrophysiological , and functional analysis	5966
regeneration	6031
animals over a 4 month observation period	6047
animals	6047
a 4 month observation period	6060
Materials and Methods Recombinant AdV stock production .	6090
Materials and Methods	6090
Materials	6090
Methods	6104
Recombinant AdV stock production	6112
Recombinant AdV	6112
stock production	6128
The production of first generation E1-deleted adenoviral vector stocks encoding the bacterial marker enzyme betta-galactosidase -LRB- betta-gal ; AdV-LacZ -RRB- -LRB- Hermens et al. , 1997 -RRB- or rat NT-3 -LRB- AdV-NT-3 -RRB- -LRB- Dijkhuizen et al. , 1997 -RRB-	6146
The production	6146
first generation E1-deleted adenoviral vector stocks encoding the bacterial marker enzyme betta-galactosidase -LRB- betta-gal ; AdV-LacZ -RRB- -LRB- Hermens et al. , 1997 -RRB- or rat NT-3 -LRB- AdV-NT-3 -RRB- -LRB- Dijkhuizen et al. , 1997 -RRB-	6164
first generation E1-deleted adenoviral vector stocks	6164
the bacterial marker enzyme betta-galactosidase -LRB- betta-gal ; AdV-LacZ -RRB- -LRB- Hermens et al. , 1997 -RRB- or rat NT-3 -LRB- AdV-NT-3 -RRB- -LRB- Dijkhuizen et al. , 1997 -RRB-	6226
the bacterial marker enzyme betta-galactosidase -LRB- betta-gal ; AdV-LacZ -RRB- -LRB- Hermens et al. , 1997 -RRB-	6226
the bacterial marker enzyme betta-galactosidase -LRB- betta-gal ; AdV-LacZ -RRB-	6226
the bacterial marker enzyme betta-galactosidase	6226
betta-gal ; AdV-LacZ	6275
betta-gal	6275
AdV-LacZ	6286
Hermens	6297
et al. , 1997	6305
et al.	6305
1997	6313
rat NT-3 -LRB- AdV-NT-3 -RRB- -LRB- Dijkhuizen et al. , 1997 -RRB-	6322
rat NT-3 -LRB- AdV-NT-3 -RRB-	6322
rat NT-3	6322
AdV-NT-3	6332
Dijkhuizen	6343
et al. , 1997	6354
et al.	6354
1997	6362
detail	6401
the construction of an AdV vector-encoding BDNF	6413
the construction	6413
an AdV vector-encoding BDNF	6433
total RNA	6462
adult rat brain	6490
First strand cDNA	6507
reverse transcriptase -LRB- Invitrogen , Grand Island , NY -RRB- and oligo-dT primers	6547
reverse transcriptase	6547
Invitrogen	6570
Grand Island	6582
NY	6596
oligo-dT primers	6604
BDNF cDNA	6636
the total cDNA via a PCR using an upstream sense primer 5 ' - CCC GGA ATT CGC CAC CAT GAC CAT CCT TTT CCT TAC T-3 ' and downstream antisense primer 5 ' - TTT AGA ATT CCT ATC TTC CCC TTT TAA TTG GT-3 ' -LRB- Amersham Biosciences , Piscataway , NJ -RRB-	6665
the total cDNA	6665
a PCR using an upstream sense primer 5 ' - CCC GGA ATT CGC CAC CAT GAC CAT CCT TTT CCT TAC T-3 ' and downstream antisense primer 5 ' - TTT AGA ATT CCT ATC TTC CCC TTT TAA TTG GT-3 ' -LRB- Amersham Biosciences , Piscataway , NJ -RRB-	6684
a PCR	6684
an upstream sense primer 5 ' - CCC GGA ATT CGC CAC CAT GAC CAT CCT TTT CCT TAC T-3 ' and downstream antisense primer 5 ' - TTT AGA ATT CCT ATC TTC CCC TTT TAA TTG GT-3 ' -LRB- Amersham Biosciences , Piscataway , NJ -RRB-	6696
an upstream sense primer 5	6696
an upstream sense primer	6696
CCC GGA ATT CGC CAC CAT GAC CAT CCT TTT CCT TAC T-3 '	6724
downstream antisense primer 5 ' - TTT AGA ATT CCT ATC TTC CCC TTT TAA TTG GT-3 ' -LRB- Amersham Biosciences , Piscataway , NJ -RRB-	6781
downstream antisense primer 5	6781
downstream antisense primer	6781
5	6809
TTT AGA	6812
ATT CCT ATC TTC CCC TTT TAA TTG GT-3 ' -LRB- Amersham Biosciences , Piscataway , NJ -RRB-	6820
ATT CCT ATC TTC CCC TTT TAA TTG GT-3 '	6820
Amersham Biosciences	6859
Piscataway	6881
NJ	6893
Primer sets	6898
an EcoR1 site and a Kozak sequence -LRB- GCCACC ; Kozak , 1987 -RRB-	6934
an EcoR1 site	6934
a Kozak sequence -LRB- GCCACC ; Kozak , 1987 -RRB-	6952
a Kozak sequence	6952
GCCACC ; Kozak , 1987	6970
GCCACC	6970
Kozak , 1987	6978
Kozak	6978
1987	6985
front of the translation startcodon ATG	7010
front	7010
the translation startcodon ATG	7019
The PCR product	7051
the expression plasmid pcDNA-I/Amp -LRB- Invitrogen -RRB-	7089
the expression plasmid pcDNA-I/Amp	7089
Invitrogen	7125
downstream of the human cytomegalovirus -LRB- CMV -RRB- promoter	7137
downstream	7137
the human cytomegalovirus -LRB- CMV -RRB- promoter	7151
CMV	7178
Nucleic acid sequencing	7193
the PCR product	7243
rat BDNF cDNA using the United States Biochemicals sequencing kit	7262
rat BDNF cDNA	7262
the United States Biochemicals sequencing kit	7282
United States Biochemicals , Cleveland , OH	7329
United States Biochemicals	7329
Cleveland	7357
OH	7368
BDNF cDNA	7379
the AdV-targeting plasmid pAd309 dlE1.sl / SalI	7403
the AdV-targeting plasmid pAd309 dlE1.sl	7403
SalI	7445
the plasmid pAd-BDNF	7461
All targeting plasmids	7483
LacZ , BDNF , or NT-3	7516
LacZ	7516
BDNF	7522
NT-3	7531
a transgene expression cassette	7561
the CMV promoter	7598
transgene expression and an SV-40 splice donor -- acceptor site and polyadenylation sequence downstream of the gene of interest	7624
transgene expression and an SV-40 splice donor	7624
transgene expression	7624
an SV-40 splice donor	7649
acceptor site and polyadenylation sequence downstream of the gene of interest	7671
acceptor site and polyadenylation sequence downstream	7671
the gene of interest	7728
the gene	7728
interest	7740
Replication-deficient E1-deleted AdV vectors	7750
standard procedures -LRB- Akli et al. , 1993 -RRB-	7815
standard procedures	7815
Akli et al. , 1993	7836
Akli	7836
et al.	7841
1993	7849
brief	7859
AdV-targeting plasmid	7866
SalI digestion	7906
plasmid	7943
ClaI	7979
XbaI-digested Ad5 DNA	7989
911 producer cells -LRB- Fallaux et al. , 1996 -RRB-	8016
911 producer cells	8016
Fallaux	8036
et al. , 1996	8044
et al.	8044
1996	8052
The following day	8059
cells	8078
0.66 % agar-containing medium -LRB- Invitrogen -RRB-	8103
0.66 % agar-containing medium	8103
0.66 %	8103
Invitrogen	8133
8 d	8152
lytic plaques	8157
PCR	8206
Plaque-purified recombinant AdV vector	8211
911 cells	8271
two rounds of CsCl density gradient centrifugation	8309
two rounds	8309
CsCl density gradient centrifugation	8323
Recombinant AdV vector particles	8361
the gradient	8414
TS buffer -LRB- 25mM Tris-HCl , 0.7 mM Na2HPO4 , 137mM NaCl , 6mM KCl , 1.1 mM MgCl2 , 0.9 mM CaCl2 -RRB- , pH 7.4 ,	8445
TS buffer -LRB- 25mM Tris-HCl , 0.7 mM Na2HPO4 , 137mM NaCl , 6mM KCl , 1.1 mM MgCl2 , 0.9 mM CaCl2 -RRB-	8445
TS buffer	8445
25mM Tris-HCl , 0.7 mM Na2HPO4 , 137mM NaCl , 6mM KCl , 1.1 mM MgCl2 , 0.9 mM CaCl2	8456
25mM Tris-HCl	8456
0.7 mM Na2HPO4	8471
137mM NaCl	8486
6mM KCl	8498
1.1 mM MgCl2	8507
0.9 mM CaCl2	8521
pH 7.4	8535
small aliquots	8557
80 °C in TS buffer	8575
80 °C	8575
TS buffer	8583
10 % glycerol	8604
Viral stock titers	8618
a plaque assay on 911 cells	8656
a plaque assay	8656
911 cells	8674
plaque-forming units per milliliter -LRB- pfu/ml -RRB-	8701
plaque-forming units	8701
milliliter -LRB- pfu/ml -RRB-	8726
milliliter	8726
pfu/ml	8738
All stock titers used	8747
All stock titers	8747
the range of 1010 pfu/ml	8777
the range	8777
1010 pfu/ml	8790
use	8810
recombinant AdV vector stocks	8815
the absence of replication-competent adenovirus as described previously -LRB- Hermens et al. , 1997 -RRB-	8863
the absence	8863
replication-competent adenovirus as described previously	8878
replication-competent adenovirus as	8878
Hermens	8936
et al. , 1997	8944
et al.	8944
1997	8952
Culturing of OEG .	8959
Culturing	8959
OEG	8972
The isolation of OEG from the olfactory bulb nerve layer	8977
The isolation	8977
OEG from the olfactory bulb nerve layer	8994
OEG	8994
the olfactory bulb nerve layer	9003
Yan et al. , 2001	9065
Yan	9065
et al.	9069
2001	9077
adult female Fischer F344 rats	9093
intraperitoneal injection of a lethal dose of Nembutal -LRB- Rhoˆne-Me ' rieux , Pinkenba , QLD , Australia -RRB-	9139
intraperitoneal injection	9139
a lethal dose of Nembutal -LRB- Rhoˆne-Me ' rieux , Pinkenba , QLD , Australia -RRB-	9168
a lethal dose	9168
Nembutal -LRB- Rhoˆne-Me ' rieux , Pinkenba , QLD , Australia -RRB-	9185
Nembutal	9185
Rhoˆne-Me ' rieux , Pinkenba , QLD , Australia	9196
Rhoˆne-Me ' rieux	9196
Rhoˆne-Me '	9196
Pinkenba , QLD , Australia	9213
The olfactory bulbs	9256
Leibovitz 's -15 -LRB- L-15 -RRB- medium -LRB- Sigma , St Louis , MO -RRB-	9318
Leibovitz 's	9318
-15 -LRB- L-15 -RRB- medium -LRB- Sigma , St Louis , MO -RRB-	9329
-15 -LRB- L-15 -RRB- medium	9329
Sigma	9348
St Louis	9355
MO	9365
The pia	9370
a microscope	9411
fine Dumont forceps	9430
the ventral olfactory nerve and glomerular layers	9457
the ventral olfactory nerve	9457
glomerular layers	9489
the rest of the bulb and cut	9532
the rest	9532
the bulb and cut	9544
1mm3 pieces	9566
tissue blocks	9593
0.25 % trypsin -LRB- Invitrogen -RRB-	9627
0.25 % trypsin	9627
Invitrogen	9642
50 mg/ml DNase -LRB- Invitrogen -RRB- at 37 °C for 60 min	9665
50 mg/ml DNase -LRB- Invitrogen -RRB-	9665
50 mg/ml DNase	9665
Invitrogen	9681
37 °C for 60 min	9696
37 °C	9696
60 min	9705
continual shaking	9717
Trypsinization	9736
DMEM -LRB- Sigma -RRB- and Ham 's F-12 -LRB- DMEM/F -12 ; 1:1 mixture ; Sigma -RRB- supplemented with 10 % fetal bovine serum -LRB- FBS ; df-10S ; Invitrogen -RRB- and 50 mg/ml gentamicin -LRB- Invitrogen -RRB-	9773
DMEM -LRB- Sigma -RRB-	9773
DMEM	9773
Sigma	9779
Ham 's F-12 -LRB- DMEM/F -12 ; 1:1 mixture ; Sigma -RRB- supplemented with 10 % fetal bovine serum -LRB- FBS ; df-10S ; Invitrogen -RRB- and 50 mg/ml gentamicin -LRB- Invitrogen -RRB-	9790
Ham 's F-12 -LRB- DMEM/F -12 ; 1:1 mixture ; Sigma -RRB-	9790
Ham 's F-12	9790
Ham 's	9790
DMEM/F -12	9802
1:1 mixture ; Sigma	9813
1:1 mixture	9813
Sigma	9826
10 % fetal bovine serum -LRB- FBS ; df-10S ; Invitrogen -RRB- and 50 mg/ml gentamicin -LRB- Invitrogen -RRB-	9851
10 % fetal bovine serum -LRB- FBS ; df-10S ; Invitrogen -RRB-	9851
10 % fetal bovine serum	9851
FBS	9875
df-10S ; Invitrogen	9880
df-10S	9880
Invitrogen	9888
50 mg/ml gentamicin -LRB- Invitrogen -RRB-	9904
50 mg/ml gentamicin	9904
Invitrogen	9925
The suspension	9938
poly-L-lysinecoated 10 cm dishes	9996
10	10016
Six to seven days after the initial plating , OEG	10030
Six	10030
seven days after the initial plating , OEG	10037
seven days	10037
the initial plating , OEG	10054
the initial plating	10054
OEG	10075
contaminated cells	10098
immunoaffinity using the p75 neurotrophin receptor -LRB- p75NTR -RRB-	10120
immunoaffinity	10120
the p75 neurotrophin receptor -LRB- p75NTR -RRB-	10141
the p75 neurotrophin receptor	10141
p75NTR	10172
this	10185
10cmPetri dishes -LRB- Scot Scientific , Perth , WA , Australia -RRB-	10191
10cmPetri dishes	10191
Scot Scientific	10209
Perth	10226
WA , Australia	10233
4 °C with goat antimouse antibodies -LRB- 1:100 ; ICN Biomedicals , Seven Hills , NSW , Australia -RRB-	10276
4 °C	10276
goat antimouse antibodies -LRB- 1:100 ; ICN Biomedicals , Seven Hills , NSW , Australia -RRB-	10285
goat antimouse antibodies	10285
1:100	10312
ICN Biomedicals , Seven Hills , NSW , Australia	10319
ICN Biomedicals	10319
Seven Hills	10336
NSW	10349
Australia	10354
several washes	10372
the dishes	10388
p75NTR monoclonal antibody	10419
Dr. P. Wood , University of Miami School of Medicine , Miami , FL	10470
Dr. P. Wood	10470
University of Miami School of Medicine , Miami , FL	10483
University	10483
Miami School of Medicine , Miami , FL	10497
Miami School	10497
Medicine , Miami , FL	10513
L-15 medium supplemented with 5 % FBS for 2 hr at 4 °C	10537
L-15 medium	10537
5 % FBS for 2 hr	10567
5 % FBS	10567
2 hr	10578
4 °C	10586
Unbound antibody	10591
several washings	10623
The cells in primary culture	10658
The cells	10658
primary culture	10671
trypsinization	10709
centrifugation	10737
a 10 ml suspension of olfactory bulb cells	10791
a 10 ml suspension	10791
olfactory bulb cells	10813
pretreated dishes	10850
a density of 4	10871
a density	10871
4	10884
10	10888
5 cells per dish	10891
5 cells	10891
dish	10903
30 min at 4 °C	10912
30 min	10912
4 °C	10922
Unbound cells	10927
the dishes	10959
several washes	10977
The attached cells	11010
the dishes	11059
a cell scraper -LRB- Sarstedt , Newton , NC -RRB-	11076
a cell scraper	11076
Sarstedt	11092
Newton	11102
NC	11110
df-10S	11147
cells	11164
poly-Llysine - coated 10 cm dishes	11192
poly-Llysine	11192
coated 10 cm dishes	11206
coated	11206
10 cm dishes	11213
df-10S	11239
mitogens -LRB- 20 µg/ml pituitary extract and 2 µM forskolin ; Sigma -RRB-	11257
mitogens	11257
20 µg/ml pituitary extract and 2 µM forskolin ; Sigma	11267
20 µg/ml pituitary extract	11267
20 µg/ml	11267
pituitary extract	11276
2 µM forskolin ; Sigma	11298
2 µM forskolin	11298
Sigma	11314
Transduction of OEG cultures with AdV vectors .	11322
Transduction	11322
OEG cultures	11338
AdV vectors	11356
The methods for optimal transduction of primary OEG	11369
The methods	11369
optimal transduction of primary OEG	11385
optimal transduction	11385
primary OEG	11409
AdV	11427
vector-mediated gene transfer	11431
Ruitenberg et al. , 2002	11491
Ruitenberg	11491
et al.	11502
2002	11510
cells	11526
poly-L-lysine-coated six-well plates	11549
a density of 105 cells per well	11589
a density	11589
105 cells per well	11602
105 cells	11602
OEG	11622
overnight with df-10S supplemented with mitogens -LRB- see above -RRB-	11640
overnight with df-10S	11640
overnight	11640
df-10S	11655
mitogens	11680
The following day	11702
the medium	11721
df-10S	11750
a lowered mitogen concentration -LRB- 2 µg/ml pituitary extract and 0.2 µM forskolin -RRB-	11768
a lowered mitogen concentration	11768
2 µg/ml pituitary extract and 0.2 µM forskolin	11801
2 µg/ml pituitary extract	11801
0.2 µM forskolin	11831
OEG proliferation	11861
AdV vectors	11888
the host cell genome	11922
proliferation of transduced OEG	11944
proliferation	11944
OEG	11972
the loss of episomally located viral DNA and , consequently , transgene expression	11989
the loss	11989
episomally located viral DNA and , consequently , transgene expression	12001
episomally located viral DNA and , consequently , transgene	12001
episomally located viral DNA	12001
transgene	12049
Recombinant AdV vector encoding betta-gal , BDNF , or NT-3	12071
Recombinant AdV vector	12071
betta-gal , BDNF , or NT-3	12103
betta-gal	12103
BDNF	12114
NT-3	12123
each	12141
a multiplicity of infection -LRB- moi -RRB- of 100	12156
a multiplicity	12156
infection -LRB- moi -RRB- of 100	12174
infection -LRB- moi -RRB-	12174
infection	12174
moi	12185
100	12193
the transduction of virtually all cultured cells -LRB- Ruitenberg et al. , 2002 -RRB-	12211
the transduction	12211
virtually all cultured cells -LRB- Ruitenberg et al. , 2002 -RRB-	12231
virtually all	12231
cells -LRB- Ruitenberg et al. , 2002 -RRB-	12254
cells	12254
Ruitenberg	12261
et al. , 2002	12272
et al.	12272
2002	12280
Three days	12287
infection	12304
OEG cultures	12315
4 % paraformaldehyde -LRB- PFA -RRB- and 0.2 % glutaraldehyde	12344
4 % paraformaldehyde -LRB- PFA -RRB-	12344
4 % paraformaldehyde	12344
PFA	12365
0.2 % glutaraldehyde	12374
PBS	12397
10 min at room temperature -LRB- RT -RRB-	12405
10 min	12405
room temperature -LRB- RT -RRB-	12415
room temperature	12415
RT	12433
OEG cultures	12449
hybridization analysis , as described by Giger et al. -LRB- 1996 -RRB- , using digoxigenin -LRB- DIG -RRB- - labeled antisense cRNA probes specific for betta-gal , BDNF , or NT-3	12508
hybridization analysis	12508
Giger	12548
et al. -LRB- 1996 -RRB-	12554
et al.	12554
1996	12562
digoxigenin -LRB- DIG -RRB- - labeled antisense cRNA probes specific for betta-gal , BDNF , or NT-3	12575
digoxigenin	12575
DIG	12588
antisense cRNA probes	12601
betta-gal , BDNF , or NT-3	12636
betta-gal	12636
BDNF	12647
NT-3	12656
Neurotrophin production from	12662
Neurotrophin production	12662
OEG	12702
Conditioned medium	12707
OEG cultures	12756
the levels of secreted AdV vector-derived BDNF and NT-3 via an ELISA	12782
the levels	12782
AdV vector-derived BDNF and NT-3 via an ELISA	12805
AdV vector-derived BDNF	12805
NT-3 via an ELISA	12833
NT-3	12833
an ELISA	12842
Woodhall	12868
et al. -LRB- 2001 -RRB-	12877
et al.	12877
2001	12885
cultures of OEG	12903
cultures	12903
OEG	12915
Three days	12953
infection	12970
the medium	12981
the cultures	13010
24 hr	13037
determination of net production levels per day	13053
determination	13053
net production levels per day	13070
net production levels	13070
day	13096
Samples of conditioned medium	13101
Samples	13101
conditioned medium	13112
control	13142
OEG cultures	13165
dry ice -- ethanol	13201
-80 °C	13231
additional processing	13243
The Emax immunoassay system -LRB- Promega , Leiden , The Netherlands -RRB-	13266
The Emax immunoassay system	13266
Promega	13295
Leiden	13304
The Netherlands	13312
the levels of neurotrophic factor protein in OEGconditioned medium	13351
the levels	13351
neurotrophic factor protein in OEGconditioned medium	13365
neurotrophic factor protein	13365
OEGconditioned medium	13396
the instructions of the manufacturer	13431
the instructions	13431
the manufacturer	13451
The amount of secreted neurotrophic factor	13469
The amount	13469
neurotrophic factor	13492
nanograms of BDNF or NT-3 derived from a transduced OEG culture -LRB- 10 5 cells -RRB- per day	13529
nanograms	13529
BDNF or NT-3	13542
a transduced OEG culture -LRB- 10 5 cells -RRB- per day	13568
a	13568
OEG culture -LRB- 10 5 cells -RRB- per day	13581
OEG culture -LRB- 10 5 cells -RRB-	13581
OEG culture	13581
10 5 cells	13594
day	13610
Biological activity of AdV vector-derived neurotrophins .	13615
Biological activity	13615
AdV vector-derived neurotrophins	13638
recombinant BDNF and NT-3 protein	13693
recombinant BDNF	13693
NT-3 protein	13714
we	13752
their effect	13763
neurite outgrowth	13779
embryonic dorsal root ganglion -LRB- DRG -RRB- explants	13802
Dijkhuizen	13864
et al. -LRB- 1997 -RRB-	13875
et al.	13875
1997	13883
OEG -LRB- 10 ^ 4 cells -RRB-	13899
OEG	13899
10 ^ 4 cells	13904
10 ^	13904
4 cells	13907
poly-L-lysine-coated 12 mm glass coverslips	13933
AdV-LacZ , AdV-BDNF , AdV-NT-3 , or no virus	13995
AdV-LacZ	13995
AdV-BDNF	14005
AdV-NT-3	14015
no virus	14028
Three days	14072
AdV vector-mediated transduction of OEG cultures	14089
AdV vector-mediated transduction	14089
OEG cultures	14125
embryonic DRGs	14139
timed pregnant female rats	14172
embryonic day -LRB- E -RRB- 14 pregnant females	14209
embryonic day -LRB- E -RRB-	14209
14 pregnant females	14227
an intraperitoneal overdose of Nembutal	14262
an intraperitoneal overdose	14262
Nembutal	14293
the entire litter	14325
Cesarean section	14366
wet icecooled L-15 medium	14402
E14 lumbar DRGs	14429
rat embryos	14482
ice-cold L-15 medium	14508
DRGs	14539
DMEM/F -12 medium -LRB- 1:1 mixture -RRB-	14577
DMEM/F -12 medium	14577
1:1 mixture	14595
the medium from OEG cultures	14613
the medium	14613
OEG cultures	14629
aspiration	14657
Single DRGs	14669
50 l of DMEM/F -12 medium	14698
50 l	14698
DMEM/F -12 medium	14706
top of AdV vector-transduced OEG monolayers	14737
top	14737
AdV vector-transduced OEG monolayers	14744
Cocultures of OEG and DRG explants	14782
Cocultures	14782
OEG and DRG explants	14796
an additional 24 hr in a CO2 incubator -LRB- 5 % -RRB-	14832
an additional 24 hr	14832
a CO2 incubator -LRB- 5 % -RRB-	14855
a CO2 incubator	14855
5 %	14872
37 °C	14879
neurite outgrowth	14898
cocultures	14917
4 % PFA in PBS	14944
4 % PFA	14944
PBS	14954
30 min	14962
cultures	14976
several times	15010
Tris-buffered saline -LRB- TBS ; 10 mM Tris-HCl , 135 mM NaCl -RRB- , pH 7.4	15029
Tris-buffered saline -LRB- TBS ; 10 mM Tris-HCl , 135 mM NaCl -RRB-	15029
Tris-buffered saline	15029
TBS ; 10 mM Tris-HCl , 135 mM NaCl	15051
TBS	15051
10 mM Tris-HCl , 135 mM NaCl	15056
10 mM Tris-HCl	15056
135 mM NaCl	15072
pH 7.4	15086
TBS containing 0.3 % Triton X-100 and 5 % FBS	15117
TBS	15117
0.3 % Triton X-100 and 5 % FBS	15132
0.3 % Triton X-100	15132
5 % FBS	15154
Cultures	15162
overnight with the mouse monoclonal antibody 2H3	15191
overnight	15191
the mouse monoclonal antibody 2H3	15206
rat neurofilament -LRB- NF -RRB- -LRB- 1:1000 ; Developmental Studies Hybridoma Bank , University of Iowa , Iowa City , IA -RRB-	15248
rat neurofilament -LRB- NF -RRB-	15248
rat neurofilament	15248
NF	15267
1:1000 ; Developmental Studies Hybridoma Bank , University of Iowa , Iowa City , IA	15272
1:1000	15272
Developmental Studies Hybridoma Bank , University of Iowa , Iowa City , IA	15280
Developmental Studies Hybridoma Bank , University	15280
Iowa , Iowa City , IA	15332
4 °C	15356
The following day	15361
cultures	15380
three times	15401
TBS	15418
Cy3-conjugated secondary antibody -LSB- 1:400 ; donkey anti-mouse -LRB- DAM -RRB- - Cy3 ; Jackson ImmunoResearch , West Grove , PA -RSB-	15441
Cy3-conjugated secondary antibody -LSB- 1:400	15441
Cy3-conjugated secondary antibody	15441
1:400	15476
DAM	15502
Cy3	15507
Jackson ImmunoResearch	15512
West Grove , PA -RSB-	15536
West Grove	15536
PA	15548
cocultures	15562
Vectashield -LRB- Vector Laboratories , Burlingame , CA -RRB-	15589
Vectashield	15589
Vector Laboratories	15602
Burlingame	15623
CA	15635
Digital photographic images of neurite outgrowth from each DRG explant	15657
Digital photographic images	15657
neurite outgrowth from each DRG explant	15688
neurite outgrowth	15688
each DRG explant	15711
a Zeiss -LRB- Thornwood , NY -RRB- confocal laser-scanning microscope -LRB- CLSM -RRB-	15753
a Zeiss -LRB- Thornwood , NY -RRB- confocal laser-scanning microscope	15753
a Zeiss	15753
Thornwood	15762
NY	15773
confocal laser-scanning microscope	15777
CLSM	15813
Preparation of OEG for spinal implantation .	15820
Preparation	15820
OEG	15835
spinal implantation	15843
Suspensions of OEG for implantation purposes	15864
Suspensions	15864
OEG for implantation purposes	15879
OEG	15879
implantation purposes	15887
Ruitenberg et al. , 2002	15948
Ruitenberg	15948
et al.	15959
2002	15967
Primary p75NTR-purified OEG	15974
poly	16019
L-lysine-coated 6 cm dishes at a density of 10 ^ 6 cells per plate and grown overnight in df-10S	16025
L-lysine-coated 6 cm dishes	16025
6	16041
a density of 10 ^ 6 cells per plate and grown overnight in df-10S	16056
a density	16056
10 ^ 6 cells per plate and grown overnight in df-10S	16069
10 ^ 6 cells per plate	16069
10 ^ 6 cells	16069
plate	16084
grown overnight in df-10S	16094
grown overnight	16094
df-10S	16113
2 µg/ml of pituitary extract and 0.2 µM forskolin	16131
2 µg/ml	16131
pituitary extract and 0.2 µM forskolin	16142
pituitary extract	16142
0.2 µM forskolin	16164
The following day	16182
the medium	16201
fresh medium containing either no AdV vector or 108 pfu -LRB- moi , 100 -RRB- AdV-LacZ , AdV-BDNF , AdV-NT-3 , or AdV-BDNF plus AdV-NT-3 , respectively , and the cells were left for 72 hr	16230
fresh medium	16230
no AdV vector or 108 pfu -LRB- moi , 100 -RRB- AdV-LacZ , AdV-BDNF , AdV-NT-3 , or AdV-BDNF plus AdV-NT-3 , respectively , and the cells were left for 72 hr	16261
no AdV vector	16261
108 pfu -LRB- moi , 100 -RRB- AdV-LacZ , AdV-BDNF , AdV-NT-3 , or AdV-BDNF plus AdV-NT-3 , respectively , and the cells were left for 72 hr	16278
108 pfu	16278
moi , 100	16287
moi	16287
100	16292
AdV-LacZ , AdV-BDNF , AdV-NT-3 , or AdV-BDNF plus AdV-NT-3 , respectively , and the cells	16297
AdV-LacZ , AdV-BDNF , AdV-NT-3 , or AdV-BDNF	16297
AdV-NT-3 , respectively	16344
AdV-NT-3	16344
the cells	16372
72 hr	16396
OEG cultures	16403
10 µg/ml of Hoechst 33342	16442
10 µg/ml	16442
Hoechst 33342	16454
bis-benzimide ; Sigma	16473
bis-benzimide	16473
Sigma	16488
several times	16519
the cells	16557
trypsinization	16584
serum-free DMEM/F -12 medium	16619
Cells	16648
low-speed centrifugation	16671
the appropriate volume of DMEM/F -12 medium	16735
the appropriate volume	16735
DMEM/F -12 medium	16761
a suspension of 105OEGper microliter	16788
a suspension	16788
105OEGper microliter	16804
The viability of OEG suspensions	16853
The viability	16853
OEG suspensions	16870
the percentage of dead cells using Trypan blue staining	16913
the percentage	16913
dead cells using Trypan blue staining	16931
dead cells	16931
Trypan blue staining	16948
all cases	16973
the viability of OEG suspensions before implantation	16984
the viability	16984
OEG suspensions before implantation	17001
OEG suspensions	17001
implantation	17024
≈ 95 %	17041
Suspensions	17047
wet ice	17077
surgery	17092
Experimental design .	17101
A total of 68 adult female Fischer F344 rats -LRB- 175 -- 200 gm ; Harlan-Olac , Oxon , UK -RRB-	17122
A total of 68 adult female Fischer F344 rats	17122
A total	17122
68 adult female Fischer F344 rats	17133
175	17168
200 gm ; Harlan-Olac , Oxon , UK	17173
200 gm	17173
Harlan-Olac , Oxon , UK	17181
this experiment	17217
All rats	17234
standard conditions	17261
a 12 hr light/dark cycle	17296
ad libitum access to water and food	17330
ad libitum access	17330
water and food	17351
All experimental procedures	17367
accordance	17413
the guidelines of the local animal welfare committee for use and care of laboratory animals	17429
the guidelines	17429
the local animal welfare committee for use and care of laboratory animals	17447
the local animal welfare committee	17447
use and care of laboratory animals	17486
use and care	17486
laboratory animals	17502
Body weight of experimental animals	17522
Body weight	17522
experimental animals	17537
the experiment as a general measure of health	17579
the experiment	17579
a general measure of health	17597
a general measure	17597
health	17618
Animals	17626
six experimental groups	17652
Experimental group 1 -LRB- n = 10 -RRB- , which serves as a control ,	17677
Experimental group 1	17677
n	17699
10	17703
a control	17724
a unilateral transection of the dorsolateral funiculus of the cervical spinal cord	17752
a unilateral transection	17752
the dorsolateral funiculus of the cervical spinal cord	17780
the dorsolateral funiculus	17780
the cervical spinal cord	17810
Rats in experimental groups 2 , 3 , 4 , 5 , and 6 received a similar spinal cord lesion but also an	17836
Rats	17836
experimental groups 2 , 3 , 4 , 5 , and 6 received a similar spinal cord lesion but also an	17844
experimental	17844
groups 2 , 3 , 4 , 5 , and 6	17857
a similar spinal cord lesion but also an	17891
a similar spinal cord lesion	17891
an	17929
either control or AdV vector-transduced OEG	17943
control	17950
AdV vector-transduced OEG	17961
Animals in groups 2 and 3	17988
Animals	17988
groups 2 and 3	17999
an	18023
uninfected OEG -LRB- n = 10 -RRB- or AdV-LacZ-transduced OEG -LRB- n = 12 -RRB-	18037
uninfected OEG	18037
n	18053
10	18057
AdV-LacZ-transduced OEG	18064
n	18089
12	18093
These groups	18112
additional controls	18135
groups 4 , 5 , and 6	18159
groups	18159
4 , 5 , and 6	18166
OEG	18179
infection	18201
AdV vectors encoding BDNF or NT-3 before implantation	18216
AdV vectors	18216
BDNF or NT-3	18237
implantation	18257
Rats in experimental groups 4 and 5	18271
Rats	18271
experimental groups 4 and 5	18279
experimental groups	18279
an	18316
AdV-BDNF -LRB- n = 12 -RRB- or AdV-NT-3-transduced -LRB- n = 12 -RRB- OEG	18330
AdV-BDNF -LRB- n = 12 -RRB-	18330
AdV-BDNF	18330
n	18340
12	18344
AdV-NT-3-transduced -LRB- n = 12 -RRB- OEG	18351
n = 12	18372
n	18372
= 12	18373
group 6	18400
OEG	18409
infection	18431
a 1:1 mixture of BDNF - and NT-3-encoding AdV vector	18446
a 1:1 mixture	18446
BDNF	18463
NT-3-encoding AdV vector	18473
the lesioned spinal cord -LRB- n = 12 -RRB-	18528
the lesioned spinal cord	18528
n	18554
12	18558
All rats	18563
4 months for recovery of hind limb performance	18595
4 months	18595
recovery of hind limb performance	18608
recovery	18608
hind limb performance	18620
Rubrospinal projections in these animals	18643
Rubrospinal projections	18643
these animals	18670
dextran amine -LRB- BDA -RRB- as a tracer	18735
dextran amine -LRB- BDA -RRB-	18735
dextran amine	18735
BDA	18750
a tracer	18758
2 weeks	18767
the animals	18782
Rubrospinal motor-evoked potentials -LRB- MEPs -RRB-	18807
Rubrospinal motor-evoked potentials	18807
MEPs	18844
all experimental animals	18868
perfusion	18900
regeneration of RST axons and integrity of descending spinal pathways in general	18919
regeneration	18919
RST axons and integrity of descending spinal pathways in general	18935
RST axons and integrity	18935
spinal pathways	18973
Seven days	19001
implantation	19018
two animals	19032
groups 3 -- 6	19060
groups	19060
3 -- 6	19067
transgene expression	19089
Surgical procedures .	19111
Surgical	19111
procedures	19120
Implantation of OEG into a unilateral cervical transection injury model involving the RST	19132
Implantation	19132
OEG into a unilateral cervical transection injury model involving the RST	19148
OEG	19148
a unilateral cervical transection injury model involving the RST	19157
a unilateral cervical transection injury model	19157
the RST	19214
detail -LRB- Ruitenberg et al. , 2002 -RRB-	19250
detail	19250
Ruitenberg	19258
et al. , 2002	19269
et al.	19269
2002	19277
brief	19287
rats	19294
intramuscular injection of ketamine -LRB- 100 mg/kg of body weight ; Nimatek , Eurovet , Bladel , The Netherlands -RRB- and xylazine -LRB- 10 mg/kg of body weight ; Bayer , Leverkussen , Germany -RRB-	19327
intramuscular injection	19327
ketamine -LRB- 100 mg/kg of body weight ; Nimatek , Eurovet , Bladel , The Netherlands -RRB- and xylazine -LRB- 10 mg/kg of body weight ; Bayer , Leverkussen , Germany -RRB-	19354
ketamine	19354
100 mg/kg of body weight ; Nimatek , Eurovet , Bladel , The Netherlands	19364
100 mg/kg	19364
body weight ; Nimatek , Eurovet , Bladel , The Netherlands	19377
body weight	19377
Nimatek , Eurovet , Bladel , The Netherlands	19390
Nimatek , Eurovet , Bladel ,	19390
The Netherlands	19416
xylazine	19437
10 mg/kg of body weight ; Bayer , Leverkussen , Germany	19447
10 mg/kg	19447
body weight ; Bayer , Leverkussen , Germany	19459
body weight	19459
Bayer , Leverkussen , Germany	19472
Access to the spinal cord	19502
Access	19502
the spinal cord	19512
dorsal laminectomy of the fourth cervical vertebra	19545
dorsal laminectomy	19545
the fourth cervical vertebra	19567
splitting the neck musculature	19602
splitting	19602
the neck musculature	19612
the spinal cord	19644
a small incision	19661
both dura and pia mater using a sharpened 30 ga needle	19695
both dura and pia mater	19695
a sharpened 30 ga needle	19725
30	19737
identification of the dorsal root entry zone and midline of the spinal cord	19757
identification of the dorsal root entry zone	19757
identification	19757
the dorsal root entry zone	19775
midline of the spinal cord	19806
midline	19806
the spinal cord	19817
the left dorsolateral funiculus of the spinal cord	19834
the left dorsolateral funiculus	19834
the spinal cord	19869
a pair of microscissors	19903
a pair	19903
microscissors	19913
deep as 1mmventral to the spinal surface , taking care not to damage the dorsal roots	19930
1mmventral to the spinal surface , taking care not to damage the dorsal	19938
1mmventral	19938
the spinal surface	19952
care	19979
the dorsal	19998
Such a lesion	20016
complete transection of the RST projection area	20042
complete transection	20042
the RST projection area	20066
the spinal gray matter	20111
OEG suspensions	20141
1 mm distance , both proximal and distal , from the lesion cavity	20184
1 mm distance	20184
the lesion cavity	20230
a Harvard microinjection apparatus	20254
Each injection	20290
105 cells	20315
removal of the injector	20332
removal	20332
the injector	20343
muscles and skin	20357
separate layers	20389
All animals	20406
a postoperative subcutaneous injection of 2 ml physiological salt solution	20427
a postoperative subcutaneous injection	20427
2 ml physiological salt solution	20469
2 ml	20469
blood loss and Finadyne -LRB- flunixinum , 2.4 mg/kg of body weight for 3 d ; Schering-Plough , Brussels , Belgium -RRB-	20520
blood loss and Finadyne	20520
flunixinum , 2.4 mg/kg of body weight for 3 d ; Schering-Plough , Brussels , Belgium	20545
flunixinum	20545
2.4 mg/kg of body weight for 3 d ; Schering-Plough , Brussels	20557
2.4 mg/kg of body weight for 3 d	20557
2.4 mg/kg	20557
body weight for 3 d	20570
body weight	20570
3 d	20586
Schering-Plough , Brussels	20591
Schering-Plough	20591
Brussels	20608
Belgium	20618
pain	20639
the end of surgical procedures	20648
the end	20648
surgical procedures	20659
the viability of OEG suspensions used for implantation	20680
the viability	20680
OEG suspensions used for implantation	20697
OEG suspensions	20697
implantation	20722
between 90 and 95 %	20748
determined by Trypan blue staining	20771
Trypan	20785
Locomotor analysis .	20807
Locomotor	20807
analysis	20817
surgery	20833
spinal cord-injured rats	20842
a period of 7 d	20895
a period	20895
7 d	20907
the assessment of locomotor capacity	20918
the assessment	20918
locomotor capacity	20936
Functional performance of the impaired hind limb	20956
Functional performance	20956
the impaired hind limb	20982
the Basso -- Beattie -- Bresnahan -LRB- BBB -RRB- locomotor rating scale -LRB- Basso et al. , 1995 -RRB-	21026
the Basso -- Beattie -- Bresnahan -LRB- BBB -RRB- locomotor rating scale	21026
Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	21030
Basso -- Beattie -- Bresnahan	21030
Beattie	21036
BBB	21055
Basso	21084
et al. , 1995	21090
et al.	21090
1995	21098
horizontal rope walking -LRB- Kim et al. , 2001 -RRB-	21115
horizontal rope walking	21115
Kim	21140
et al. , 2001	21144
et al.	21144
2001	21152
both cases	21162
gait analysis of spinal cord-injured rats	21174
gait analysis	21174
spinal cord-injured rats	21191
two independent investigators that were blinded to the treatment of the animal	21250
two independent investigators	21250
the treatment of the animal	21301
the treatment	21301
the animal	21318
The first functional assay , the BBB rating score ,	21330
The first functional assay	21330
the BBB rating score	21358
21 operational definitions studying several aspects involved in the locomotion of quadrupedal animals	21396
21 operational definitions	21396
several aspects involved in the locomotion of quadrupedal animals	21432
several aspects	21432
the locomotion of quadrupedal animals	21460
the locomotion	21460
quadrupedal animals	21478
a more sensitive test to assess behavioral deficits in partial spinal cord hemisection models	21502
behavioral deficits	21534
partial spinal cord hemisection models	21557
horizontal rope walking	21597
more specific aspects such as posture and balance	21639
more specific aspects	21639
posture and balance	21669
gait	21696
this test	21705
animals	21716
a 1.25-meter-long rope -LRB- diameter , 4 cm -RRB-	21752
a 1.25-meter-long rope	21752
diameter , 4 cm	21776
diameter	21776
4 cm	21786
one platform to another	21797
one platform	21797
another	21813
the gait of the animal	21827
the gait	21827
the animal	21839
this task , hind limb weight support , precise paw placement , and adaptable balance	21888
this task	21888
hind limb weight support	21899
precise paw placement	21925
adaptable balance	21952
Animals	21985
a period of 5 weeks	22013
a period	22013
5 weeks	22025
the start of the experiment , such	22040
the start	22040
the experiment , such	22053
the experiment	22053
such	22069
a constant rope locomotion performance	22079
Trained animals	22132
the rope	22156
an occasional minor slip	22178
no	22207
Rats	22217
their general performance	22238
rope locomotion using a deficit rating scale defined as follows : -LRB- 0 -RRB- normal rope locomotion with rare minor deficits	22271
rope locomotion	22271
a deficit rating scale defined as follows : -LRB- 0 -RRB- normal rope locomotion	22293
a deficit rating scale defined as follows	22293
a deficit rating scale	22293
-LRB- 0 -RRB- normal rope locomotion	22336
-LRB- 0 -RRB- normal rope	22336
0	22337
locomotion	22352
rare minor deficits	22368
normal locomotion	22402
occasional lesion deficits ; -LRB- 2 -RRB- able to cross the rope	22425
occasional lesion deficits	22425
-LRB- 2 -RRB- able to cross the rope	22453
able	22457
the rope	22471
obvious lesion deficits such as inability	22489
obvious lesion deficits	22489
inability	22521
consistent weight-supported limb placement during traverse ; or -LRB- 3 -RRB- great difficulty to cross the rope	22543
consistent weight-supported limb placement during traverse	22543
consistent weight-supported limb placement	22543
traverse	22593
-LRB- 3 -RRB- great difficulty to cross the rope	22606
great difficulty	22610
the rope	22636
frequent	22646
ratings	22686
rats	22695
two conditioning trials	22711
forelimb and hindlimb placement	22766
general balance and posture	22812
traverse	22847
they	22860
the rope	22877
all rats	22887
a stationary lateral view	22922
us	22958
the `` total error/step '' ratio	22974
This quantitative analysis method	23004
the number of	23056
the number	23056
rope traverse	23093
these data	23113
a total error/step ratio	23125
the following : -LSB- number of slips + 2 -LRB- number of falls -RRB- -RSB- / total number of steps	23180
the following	23180
-LSB- number of slips + 2 -LRB- number of falls -RRB- -RSB- / total number of steps	23195
number of slips + 2 -LRB- number of falls -RRB-	23196
number of slips	23196
number	23196
2 -LRB- number of falls -RRB-	23214
2	23214
number of falls	23216
number	23216
total number	23234
steps	23250
Each rat	23257
three times	23279
final scores	23296
the mean of three independent observations -LRB- quantitative analysis -RRB- or the cumulative deficit score of three runs -LRB- maximum deficit score of 9 -RRB-	23321
the mean of three independent observations -LRB- quantitative analysis -RRB-	23321
the mean	23321
three independent observations -LRB- quantitative analysis -RRB-	23333
three independent observations	23333
quantitative analysis	23365
the cumulative deficit score of three runs -LRB- maximum deficit score of 9 -RRB-	23391
the cumulative deficit score	23391
three runs -LRB- maximum deficit score of 9 -RRB-	23423
three runs	23423
maximum deficit score of 9	23435
maximum deficit score	23435
9	23460
Kim et al. -LRB- 2001 -RRB-	23477
Kim et al.	23477
Kim	23477
et al.	23481
2001	23489
RST axon tracing .	23496
RST axon	23496
Anterograde labeling of the RST	23514
Anterograde labeling	23514
the RST	23538
Antal et al. , 1992	23585
Antal	23585
et al.	23591
1992	23599
biotin -- dextran conjugates -LRB- 10 % BDA , 10,000 molecular weight in PBS -RRB- -LRB- Molecular Probes , Leiden , The Netherlands -RRB- as a neuronal tracer , 14 d	23612
biotin	23612
dextran conjugates -LRB- 10 % BDA , 10,000 molecular weight in PBS -RRB- -LRB- Molecular Probes , Leiden , The Netherlands -RRB- as a neuronal tracer	23619
dextran conjugates -LRB- 10 % BDA , 10,000 molecular weight in PBS -RRB- -LRB- Molecular Probes , Leiden , The Netherlands -RRB-	23619
dextran conjugates -LRB- 10 % BDA , 10,000 molecular weight in PBS -RRB-	23619
dextran conjugates	23619
10 % BDA , 10,000 molecular weight in PBS	23639
10 % BDA , 10,000 molecular weight	23639
10 % BDA	23639
10,000 molecular weight	23648
PBS	23675
Molecular Probes	23681
Leiden	23699
The Netherlands	23707
a neuronal tracer	23727
perfusion	23758
brief	23772
a small hole	23779
the skull	23807
deep ketamine -- xylazine anesthesia while the animal was held in a stereotaxic frame	23823
deep ketamine	23823
xylazine anesthesia while the animal was held in a stereotaxic frame	23837
xylazine anesthesia	23837
the animal	23863
a stereotaxic frame	23886
Glass pipettes with a tip diameter of 60 µm	23907
Glass pipettes	23907
a tip diameter of 60 µm	23927
a tip diameter	23927
60 µm	23945
BDA tracer that was subsequently delivered to the red nucleus using iontophoresis	23968
BDA tracer	23968
the red nucleus	24014
iontophoresis	24036
The stereotaxic	24051
tracer delivery	24083
horizontal skull position , 6 mm posterior and 0.7 mm lateral	24110
horizontal skull position	24110
6 mm posterior	24137
0.7 mm lateral	24155
bregma and 6.8 mmdeep from the dorsal surface of the brain	24172
bregma	24172
6.8 mmdeep from the dorsal surface of the brain	24183
6.8 mmdeep	24183
the dorsal surface of the brain	24198
the dorsal surface	24198
the brain	24220
A positive direct current of 6 µA -LRB- Vmax , 30 V -RRB-	24231
A positive direct current	24231
6 µA -LRB- Vmax , 30 V -RRB-	24260
6 µA	24260
Vmax , 30 V	24266
Vmax	24266
30 V	24272
a pulse duration of 5 sec followed by 5 sec intervals for a period of 20 min	24292
a pulse duration	24292
5 sec followed by 5 sec intervals for a period of 20 min	24312
5 sec	24312
5 sec intervals for a period of 20 min	24330
5 sec intervals	24330
a period of 20 min	24350
a period	24350
20 min	24362
The current	24370
the injector	24408
place for 5 min	24433
place	24433
5 min	24443
diffusion ofBDAfrom	24458
the injection spot	24478
Polarity of the current	24498
Polarity	24498
the current	24510
the careful withdrawal of the glass capillary and suturing of the skin	24552
the careful withdrawal of the glass capillary	24552
the careful withdrawal	24552
the glass capillary	24578
suturing of the skin	24602
suturing	24602
the skin	24614
Electrophysiology	24624
the end of the experiment	24646
the end	24646
the experiment	24657
conclusion of the behavioral analysis at 4 months after injury	24679
conclusion	24679
the behavioral analysis at 4 months after injury	24693
the behavioral analysis	24693
4 months after injury	24720
4 months	24720
injury	24735
rubrospinal MEPs	24743
Lankhorst et al. , 1999	24799
Lankhorst	24799
et al.	24809
1999	24817
possible RST axon regeneration	24835
animals	24876
hypnorm -LRB- 0.4 ml/kg of body weight , i.m. ; Janssen Pharmaceutical LTD , Grove , Oxford , UK -RRB- containing 0.315 mg/ml of fentanyl citrate and 10 mg/ml of fluanisone	24914
0.4 ml/kg of body weight	24923
0.4 ml/kg	24923
body weight	24936
i.m. ; Janssen Pharmaceutical LTD , Grove , Oxford , UK	24949
i.m.	24949
Janssen Pharmaceutical LTD , Grove , Oxford , UK	24955
0.315 mg/ml of fentanyl citrate and 10 mg/ml of fluanisone	25013
0.315 mg/ml of fentanyl citrate	25013
0.315 mg/ml	25013
fentanyl citrate	25028
10 mg/ml of fluanisone	25049
10 mg/ml	25049
fluanisone	25061
Hypnorm injections	25073
every 30 min	25106
induction of the anesthesia	25125
induction	25125
the anesthesia	25138
the animals	25168
a neuromuscular blockade with pancronium bromide -LRB- 1.25 mg/kg of body weight , i.v. ; Organon , Oss , The Netherlands -RRB-	25229
a neuromuscular blockade	25229
pancronium bromide -LRB- 1.25 mg/kg of body weight , i.v. ; Organon , Oss , The Netherlands -RRB-	25259
pancronium bromide	25259
1.25 mg/kg of body weight , i.v. ; Organon , Oss , The Netherlands	25279
1.25 mg/kg of body weight	25279
1.25 mg/kg	25279
body weight	25293
i.v. ; Organon	25306
i.v.	25306
Organon	25312
Oss , The Netherlands	25321
Oss	25321
The Netherlands	25326
Rubrospinal MEPs	25344
direct bipolar stimulation -LRB- SNEX-100x ; 20 mm ; Bilaney Consultants , Dusseldorf , Germany -RRB- of the lesioned right red nucleus	25378
direct bipolar stimulation -LRB- SNEX-100x ; 20 mm ; Bilaney Consultants , Dusseldorf , Germany -RRB-	25378
direct bipolar stimulation	25378
SNEX-100x ; 20 mm ; Bilaney Consultants , Dusseldorf , Germany	25406
SNEX-100x	25406
20 mm ; Bilaney Consultants , Dusseldorf , Germany	25417
20 mm	25417
Bilaney Consultants , Dusseldorf , Germany	25424
Bilaney Consultants	25424
Dusseldorf , Germany	25445
the lesioned right red nucleus	25469
stereotaxic	25501
tracer delivery	25532
vertebra C5 via an epidurally located bipolar recording electrode consisting of thin gold plates and with an interpolar distance of 5 mm	25568
vertebra C5	25568
an epidurally located bipolar recording electrode consisting of thin gold plates and with an interpolar distance of 5 mm	25584
an epidurally located bipolar recording electrode	25584
thin gold plates	25648
an interpolar distance of 5 mm	25674
an interpolar distance	25674
5 mm	25700
Threshold values	25706
the applied voltage	25773
All MEPs used for analysis	25794
All MEPs	25794
analysis	25812
twice the threshold value	25838
potentials	25887
the lesioned red nucleus and not	25916
part , the result of cross-stimulation of the intact RST	25953
part	25953
the result of cross-stimulation of the intact RST	25959
the result	25959
cross-stimulation of the intact RST	25973
cross-stimulation	25973
the intact RST	25994
the right lateral funiculus	26010
the level of vertebrae C3	26056
the level	26056
vertebrae C3	26069
Such a lesion	26083
the RST that originated from the left red nucleus , yielding the MEP signal that was attributable to stimulation of the right red nucleus	26118
the RST	26118
the left red nucleus	26147
the MEP signal that was attributable to stimulation of the right red nucleus	26178
the MEP signal	26178
stimulation of the right red nucleus	26218
stimulation	26218
the right red nucleus	26233
recording of rubrospinal MEPs	26274
recording	26274
rubrospinal MEPs	26287
animals	26305
transcardial perfusion	26328
100 ml of saline followed by 300 ml of ice-cold 4 % PFA in PBS	26356
100 ml	26356
saline followed by 300 ml of ice-cold 4 % PFA in PBS	26366
saline	26366
300 ml of ice-cold 4 % PFA in PBS	26385
300 ml	26385
ice-cold 4 % PFA in PBS	26395
ice-cold 4 % PFA	26395
PBS	26414
Brains and spinal cords	26419
Brains	26419
spinal cords	26430
postfixed overnight in 4 % PFA solution , and stored in 0.1 % PFA in PBS containing 0.01 % NaN3 at 4 °C until additional use	26469
postfixed overnight in 4 % PFA solution , and stored in 0.1 % PFA in PBS containing 0.01 % NaN3	26469
4 % PFA solution	26492
0.1 % PFA in PBS	26523
0.1 % PFA	26523
PBS	26535
0.01 %	26550
4 °C until additional use	26564
4 °C	26564
additional use	26574
MEP analysis	26594
a total of 1024 traces	26608
a total	26608
1024 traces	26619
the signal/noise ratio	26656
the mean trace	26687
deviations from the signal baseline	26703
deviations	26703
the signal baseline	26719
a peak	26758
the top-valley voltage difference	26768
at least three times as large	26806
the SD of the noise	26839
the SD	26839
the noise	26849
The amplitude and latency of the first -LRB- monosynaptic -RRB- positive peak , as well as the summed amplitudes of all peaks during the first 5 msec -LRB- stimulus artifact was discarded -RRB- ,	26860
The amplitude and latency of the first -LRB- monosynaptic -RRB- positive peak	26860
The amplitude and latency	26860
the first -LRB- monosynaptic -RRB- positive peak	26889
the summed amplitudes of all peaks during the first 5 msec -LRB- stimulus artifact was discarded -RRB-	26940
the summed amplitudes	26940
all peaks	26965
the first 5 msec	26982
stimulus artifact	27000
the analysis	27066
Histological analysis .	27080
transgene expression 7 d	27115
transgene expression	27115
implantation	27146
horizontal sections through the cervical spinal cord	27160
horizontal sections	27160
the cervical spinal cord	27188
a cryostat	27225
standard in situ hybridization using DIGlabeled cRNA	27253
standard	27253
hybridization	27270
DIGlabeled cRNA	27290
antisense probes	27306
BDNF or NT-3 mRNA	27331
Consecutive sections	27350
p75NTR	27396
the nature of transgene-expressing cells and astrocyte marker glial fibrillary acidic protein -LRB- GFAP ; 1:5000 ; Dako , Glostrup , Denmark -RRB-	27415
the nature of transgene-expressing cells	27415
the nature	27415
transgene-expressing cells	27429
astrocyte marker glial fibrillary acidic protein -LRB- GFAP ; 1:5000 ; Dako , Glostrup , Denmark -RRB-	27460
astrocyte marker	27460
glial fibrillary acidic protein -LRB- GFAP ; 1:5000 ; Dako , Glostrup , Denmark -RRB-	27477
glial fibrillary acidic protein	27477
GFAP	27510
1:5000 ; Dako , Glostrup , Denmark	27516
1:5000	27516
Dako , Glostrup , Denmark	27524
perfusion of the experimental animals , at 4 months after injury	27556
perfusion	27556
the experimental animals , at 4 months after injury	27569
the experimental animals	27569
4 months	27598
injury	27613
fixed spinal cords -LRB- cervical region , C2 -- C6 -RRB-	27621
fixed spinal cords	27621
cervical region , C2 -- C6	27641
cervical region , C2	27641
C6	27661
several times	27677
PBS	27696
10 % gelatin -LRB- Difco , Detroit , MI -RRB-	27713
10 % gelatin	27713
Difco	27726
Detroit	27733
MI	27742
48 hr in 4 % PFA solution	27765
48 hr	27765
4 % PFA solution	27774
4 °C -LRB- Griffioen et al. , 1992 -RRB-	27793
4 °C	27793
Griffioen	27798
et al. , 1992	27808
et al.	27808
1992	27816
Four series of consecutive horizontal vibratome sections -LRB- 40µm -RRB-	27823
Four series	27823
consecutive horizontal vibratome sections -LRB- 40µm -RRB-	27838
consecutive horizontal vibratome sections	27838
40µm	27881
PBS	27899
serial vials	27920
BDA-traced RST axons	27934
quantification purposes	27975
two alternate series of the horizontal spinal cord sections -LRB- 50 % of all sections -RRB-	28011
two alternate series	28011
the horizontal spinal cord sections -LRB- 50 % of all sections -RRB-	28035
the horizontal spinal cord sections	28035
50 % of all sections	28072
50 %	28072
all sections	28079
brief	28097
sections	28104
three times	28125
TBS , followed by irreversible blocking of endogenous peroxidase activity with 10 % methanol and 3 % H2O2 in TBS for 1 hr at RT.	28140
TBS	28140
irreversible blocking of endogenous peroxidase activity	28157
irreversible blocking	28157
endogenous peroxidase activity	28182
10 % methanol and 3 % H2O2	28218
10 % methanol	28218
3 % H2O2	28235
TBS for 1 hr at RT.	28246
TBS	28246
1 hr at RT.	28254
1 hr	28254
RT.	28262
sections	28280
three times	28301
30 min	28331
TBS supplemented with 5 % FBS and 0.3 % Triton X-100	28343
TBS	28343
5 % FBS and 0.3 % Triton X-100	28365
5 % FBS	28365
0.3 % Triton X-100	28376
Sections	28395
overnight with avidin -- biotin -- peroxidase complex at 4 °C -LRB- 1 : 800 avidin plus 1:800 biotin ; PK-6100 Elite Vectastain ABC-kit ; Vector Laboratories , Burlingame , CA -RRB-	28424
overnight	28424
avidin	28439
biotin	28446
peroxidase complex at 4 °C -LRB- 1 : 800 avidin plus 1:800 biotin ; PK-6100 Elite Vectastain ABC-kit ; Vector Laboratories , Burlingame , CA -RRB-	28453
peroxidase complex	28453
4 °C -LRB- 1 : 800 avidin plus 1:800 biotin ; PK-6100 Elite Vectastain ABC-kit ; Vector Laboratories , Burlingame , CA -RRB-	28475
4 °C	28475
1 : 800 avidin plus 1:800 biotin ; PK-6100 Elite Vectastain ABC-kit ; Vector Laboratories , Burlingame , CA	28480
1	28480
800 avidin plus 1:800 biotin ; PK-6100 Elite Vectastain ABC-kit ; Vector Laboratories , Burlingame , CA	28483
800 avidin plus 1:800 biotin	28483
800 avidin	28483
1:800 biotin	28499
PK-6100 Elite Vectastain ABC-kit	28513
PK-6100 Elite	28513
Vectastain ABC-kit	28527
Vector Laboratories , Burlingame , CA	28547
Vector Laboratories	28547
Burlingame , CA	28568
The following day	28585
sections	28604
three times	28625
TBS	28640
tyramid -LRB- 1:1000 ; Dako -RRB- for 10 min	28676
tyramid -LRB- 1:1000 ; Dako -RRB-	28676
tyramid	28676
1:1000 ; Dako	28685
1:1000	28685
Dako	28693
10 min	28703
TBS containing 0.01 % H2O2 to allow signal amplification	28713
TBS	28713
0.01 %	28728
H2O2 to allow signal amplification	28734
H2O2	28734
signal amplification	28748
Sections	28770
three times	28797
ABC reagent	28828
1 hr at RT.	28844
1 hr	28844
RT.	28852
several washes	28862
sections	28878
3,3 ' - diaminobenzidine tetrahydrochloride -LRB- DAB -RRB- in 50 mM Tris-HCl , pH 7.4 , containing 0.01 % H2O2 and 0.2 mg/ml of -LRB- NH4 -RRB- 2 * SO4 * NiSO4 resulting in a dark purple precipitate	28905
3,3	28905
diaminobenzidine tetrahydrochloride -LRB- DAB -RRB- in 50 mM Tris-HCl , pH 7.4 , containing 0.01 % H2O2	28910
diaminobenzidine tetrahydrochloride -LRB- DAB -RRB- in 50 mM Tris-HCl	28910
diaminobenzidine tetrahydrochloride -LRB- DAB -RRB-	28910
diaminobenzidine tetrahydrochloride	28910
DAB	28947
50 mM Tris-HCl	28955
pH 7.4	28971
0.01 % H2O2	28990
0.2 mg/ml of -LRB- NH4 -RRB- 2 * SO4 * NiSO4 resulting in a dark purple precipitate	29005
0.2 mg/ml of -LRB- NH4 -RRB- 2 *	29005
0.2 mg/ml	29005
NH4	29019
2	29023
SO4 *	29025
SO4	29025
NiSO4 resulting in a dark purple precipitate	29029
NiSO4	29029
a dark purple precipitate	29048
Sections	29075
series of ethanol , cleared in xylene ,	29123
series	29123
ethanol , cleared in xylene ,	29133
ethanol	29133
xylene	29153
Entellan -LRB- Merck , Amsterdam , The Netherlands -RRB-	29185
Entellan	29185
Merck	29195
Amsterdam	29202
The Netherlands	29213
the spatial relationship of BDA-traced RST axons with the lesion and implantation site	29251
the spatial relationship	29251
BDA-traced RST axons with the lesion and implantation site	29279
BDA-traced RST axons	29279
the lesion and implantation site	29305
camera lucida drawings of representative sections through the injured dorsolateral funiculus	29339
camera lucida drawings	29339
representative sections through the injured dorsolateral funiculus	29365
representative sections	29365
the injured dorsolateral funiculus	29397
The third set of sections	29443
The third set	29443
sections	29460
more detail	29492
the spatial relationship of BDA-traced RST axons and the glial scar using DAB double staining as described previously -LRB- Buijs et al. , 1999 -RRB-	29504
the spatial relationship	29504
BDA-traced RST axons and the glial scar using DAB double staining as described previously -LRB- Buijs et al. , 1999 -RRB-	29532
BDA-traced RST axons	29532
the glial scar using DAB double staining as described previously -LRB- Buijs et al. , 1999 -RRB-	29557
the glial scar using DAB double staining as described previously	29557
the glial scar	29557
DAB double staining	29578
Buijs	29623
et al. , 1999	29629
et al.	29629
1999	29637
this end	29647
free-floating sections	29657
overnight with ABC reagent	29729
overnight	29729
ABC reagent	29744
RST axons	29772
the DAB color reaction	29789
three washes	29828
TBS followed by a 10 min incubation with 10 % methanol and 3 % H2O2 containing TBS to block peroxidase activity	29846
TBS	29846
a 10 min incubation	29862
10 % methanol and 3 % H2O2	29887
10 % methanol	29887
3 % H2O2	29904
TBS	29923
peroxidase activity	29936
Sections	29957
overnight with a rabbit polyclonal antibody against GFAP -LRB- 1:5000 ; Dako -RRB-	29986
overnight	29986
a rabbit polyclonal antibody against GFAP -LRB- 1:5000 ; Dako -RRB-	30001
a rabbit polyclonal antibody	30001
GFAP -LRB- 1:5000 ; Dako -RRB-	30038
GFAP	30038
1:5000 ; Dako	30044
1:5000	30044
Dako	30052
4 °C	30061
The following day	30066
unbound antibodies	30085
multiple washings in TBS	30126
multiple washings	30126
TBS	30147
sections incubated with a horseradish peroxidaseconjugated secondary antibody	30156
sections	30156
a horseradish peroxidaseconjugated secondary antibody	30180
rabbit immunoglobulins -LRB- 1:200 ; Dako -RRB-	30256
rabbit immunoglobulins	30256
1:200 ; Dako	30280
1:200	30280
Dako	30287
Sections	30294
DAB as a chromogen but without the addition of -LRB- NH4 -RRB- 2 * SO4 * NISO4	30341
DAB as a chromogen but without the addition of -LRB- NH4 -RRB- 2 * SO4	30341
DAB	30341
a chromogen	30348
the addition of -LRB- NH4 -RRB- 2	30372
the addition	30372
NH4	30389
2	30393
SO4	30395
NISO4	30399
This	30406
the formation of a brown immunoprecipitate that can be clearly distinguished from dark purple-stained RST axons	30422
the formation	30422
a brown immunoprecipitate that can be clearly distinguished from dark purple-stained RST axons	30439
a brown immunoprecipitate	30439
dark purple-stained RST axons	30504
Sections	30535
gelatin-coated slides	30560
overnight	30592
RT.	30605
The sections	30609
0.2 %	30660
cresyl violet solution , dehydrated in ethanol ,	30665
cresyl violet solution	30665
ethanol	30703
Entellan	30736
The fourth and final set of vibratome sections	30765
The fourth and final set	30765
vibratome sections	30793
an impression of the severity of scar formation	30836
an impression	30836
the severity of scar formation	30853
the severity	30853
scar formation	30869
the lesion site at 4 months	30887
the lesion site	30887
4 months	30906
injury	30921
regenerating axons in the lesion area	30945
regenerating axons	30945
the lesion area	30967
this	30988
p75NTR immunoreactivity	30994
a general marker	31030
implantedOEGat	31060
the lesion site	31075
staining for NF or fibronectin	31109
staining	31109
NF or fibronectin	31122
The latter antibody	31141
p75NTR-negative meningeal cells and fibroblasts that may have invaded the lesion site -LRB- Pasterkamp et al. , 1999 -RRB-	31172
p75NTR-negative meningeal cells and fibroblasts	31172
the lesion site -LRB- Pasterkamp et al. , 1999 -RRB-	31242
the lesion site	31242
Pasterkamp	31259
et al. , 1999	31270
et al.	31270
1999	31278
brief	31288
sections	31295
three times	31316
TBS and permeabilized with TBS containing 0.3 % Triton X-100	31333
TBS containing 0.3 %	31360
TBS	31360
0.3 %	31375
5 % FBS	31397
nonspecific binding of antibodies	31413
nonspecific binding	31413
antibodies	31436
Sections	31448
overnight with primary antibodies	31477
overnight	31477
primary antibodies	31492
p75NTR -LRB- 1:50 ; mouse monoclonal antibody clone 192 ; Chemicon , Harrow , UK -RRB- and fibronectin -LRB- 1 : 50 ; rabbit polyclonal antibody ; Chemicon -RRB- or NF -LRB- 1:100 ; NF-200 ; Sigma -RRB-	31519
p75NTR -LRB- 1:50 ; mouse monoclonal antibody clone 192 ; Chemicon , Harrow , UK -RRB-	31519
p75NTR	31519
1:50 ; mouse monoclonal antibody clone 192 ; Chemicon , Harrow , UK	31527
1:50	31527
mouse monoclonal antibody clone 192 ; Chemicon , Harrow , UK	31533
mouse monoclonal antibody clone 192	31533
mouse monoclonal antibody	31533
clone 192	31559
Chemicon , Harrow , UK	31570
Chemicon	31570
Harrow , UK	31580
fibronectin -LRB- 1 : 50 ; rabbit polyclonal antibody ; Chemicon -RRB-	31596
fibronectin	31596
1 : 50 ; rabbit polyclonal antibody ; Chemicon	31609
1 : 50	31609
rabbit polyclonal antibody ; Chemicon	31616
rabbit polyclonal antibody	31616
Chemicon	31644
NF -LRB- 1:100 ; NF-200 ; Sigma -RRB-	31657
NF	31657
1:100	31661
NF-200 ; Sigma	31668
NF-200	31668
Sigma	31676
4 °C	31686
The following day	31691
sections	31710
TBS	31736
a mixture of fluorophore-conjugated secondary antibodies for 1 hr at RT : swine anti-rabbit-FITC and DAM-Cy3 -LRB- 1:400 ; Jackson ImmunoResearch -RRB-	31759
a mixture	31759
fluorophore-conjugated secondary antibodies for 1 hr at RT : swine anti-rabbit-FITC and DAM-Cy3 -LRB- 1:400 ; Jackson ImmunoResearch -RRB-	31772
fluorophore-conjugated secondary antibodies for 1 hr at RT : swine anti-rabbit-FITC and DAM-Cy3	31772
fluorophore-conjugated secondary antibodies	31772
1 hr	31820
RT	31828
swine	31832
DAM-Cy3	31859
1:400 ; Jackson ImmunoResearch	31868
1:400	31868
Jackson ImmunoResearch	31875
Sections	31900
slides	31925
Vectashield	31948
Digital photographic images	31961
a Zeiss CLSM device	32009
Quantification of RST axon numbers and lesion size .	32030
Quantification	32030
RST axon numbers and lesion size	32048
RST axon numbers	32048
lesion size	32069
regeneration or sprouting of traced RST axons	32094
regeneration or sprouting	32094
traced RST axons	32123
BDA-positive axonal profiles in the lesion area	32141
BDA-positive axonal profiles	32141
the lesion area	32173
Blits	32218
et al. -LRB- 2000 -RRB-	32224
et al.	32224
2000	32232
the proximal border of the scar	32246
the proximal border	32246
the scar	32269
a dark-field filter	32299
point 0	32338
Lesion borders	32348
a clear discontinuity of normal spinal cord cytoarchitecture , the absence of healthylooking spinal neurons , and a high density of small cells -LSB- i.e. , implanted OEG and endogenous cells -LRB- e.g. , inflammatory cells -RRB- that are known to invade spinal cord injury sites -RSB- as described previously -LRB- Takami et al. , 2002 ; Plant et al. , 2003 -RRB-	32379
a clear discontinuity	32379
normal spinal cord cytoarchitecture , the absence of healthylooking spinal neurons , and a high density of small cells -LSB- i.e. , implanted OEG and endogenous cells -LRB- e.g. , inflammatory cells -RRB- that are known to invade spinal cord injury sites -RSB- as described previously	32404
normal spinal cord cytoarchitecture	32404
the absence of healthylooking spinal neurons , and a high density of small cells -LSB- i.e. , implanted OEG and endogenous cells -LRB- e.g. , inflammatory cells -RRB- that are known to invade spinal cord injury sites -RSB- as described previously	32441
the absence	32441
healthylooking spinal neurons , and a high density of small cells -LSB- i.e. , implanted OEG and endogenous cells -LRB- e.g. , inflammatory cells -RRB-	32456
spinal neurons , and a high density of small cells	32471
spinal neurons	32471
a high density of small cells	32491
a high density	32491
small cells	32509
OEG	32538
endogenous cells -LRB- e.g. , inflammatory cells -RRB-	32546
endogenous cells	32546
e.g. , inflammatory cells	32564
e.g.	32564
inflammatory cells	32570
spinal cord injury sites	32615
Takami	32666
et al. , 2002 ; Plant et al. , 2003	32673
et al.	32673
2002 ; Plant et al.	32681
2002	32681
Plant et al.	32687
Plant	32687
et al.	32693
2003	32701
Fiber counts	32708
fixed distances up to several millimeters proximal and distal	32734
fixed distances	32734
several millimeters proximal and distal	32756
several millimeters	32756
this point	32799
this	32815
a 65 µm width frame	32821
the horizontal sections at 3 , 2 , 1.5 , 1 , 0.75 , 0.5 , 0.25 , and 0 mm proximal or distal	32858
the horizontal sections	32858
3 , 2 , 1.5 , 1 , 0.75 , 0.5 , 0.25 , and 0 mm proximal or distal	32885
3	32885
2	32888
1.5	32891
1	32896
0.75	32899
0.5	32905
0.25	32910
0 mm proximal or distal	32920
0 mm	32920
the proximal border of the lesion -LRB- point 0 -RRB-	32947
the proximal border	32947
the lesion -LRB- point 0 -RRB-	32970
the lesion	32970
point 0	32982
All BDA-positive axons visible within this frame	32992
All BDA-positive axons	32992
this frame	33030
200 magnification	33062
an independent investigator who was blinded to the treatment of the animals	33083
an independent investigator	33083
the treatment of the animals	33130
the treatment	33130
the animals	33147
variability in the tracing results	33175
variability	33175
the tracing results	33190
relative RST axon numbers	33211
the fiber	33267
each distance as a percentage of traced RST axons at 3 mm proximal to point 0	33287
each distance	33287
a percentage of traced RST axons at 3 mm proximal to point 0	33304
a percentage	33304
traced RST axons at 3 mm proximal to point 0	33320
traced RST axons	33320
3 mm proximal to point 0	33340
3 mm	33340
0	33363
possible counteracting effects of different OEG implants on the ongoing secondary degeneration at the injury site	33376
possible counteracting effects	33376
different OEG implants on the ongoing secondary degeneration at the injury site	33410
different OEG implants	33410
the ongoing secondary degeneration at the injury site	33436
the ongoing secondary degeneration	33436
the injury site	33474
lesion volumes of all experimental animals	33491
lesion volumes	33491
all experimental animals	33509
a computerized image analysis station	33556
brief	33598
the same sections used for RST axon quantification -LRB- described above ; 50 % of total sections -RRB-	33605
the same sections used for RST axon quantification	33605
the same sections	33605
RST axon quantification	33632
50 % of total sections	33674
50 %	33674
total sections	33681
darkfield microscopy	33716
the border of the damaged area	33742
the border	33742
the damaged area	33756
the same criteria	33794
lesion areas	33838
the observer	33871
the experimental treatment	33899
The outlined area	33927
scar-associated cells	33960
grafted OEG	33993
a rare occasion , some small cysts if present -LRB- primarily in unimplanted lesioned control animals -RRB-	34013
a rare occasion	34013
some small cysts if present -LRB- primarily in unimplanted lesioned control animals -RRB-	34030
some small cysts	34030
unimplanted lesioned control animals	34072
The outlined areas of each animal	34111
The outlined areas	34111
each animal	34133
Microsoft -LRB- Seattle , WA -RRB- Excel	34177
Seattle	34188
WA	34197
the section thickness	34230
the total number of sections	34271
the total number	34271
sections	34291
Statistical analysis .	34301
Data	34323
histological analysis	34342
electrophysiology , as well as the calculated total error/step ratios ,	34368
electrophysiology	34368
the calculated total error/step ratios	34398
statistical differences between animal groups -LRB- p < 0.05 -RRB-	34456
statistical differences	34456
animal groups -LRB- p < 0.05 -RRB-	34488
animal groups	34488
p < 0.05	34504
p	34504
< 0.05	34507
<	34507
0.05	34509
two-way ANOVA	34521
hoc	34544
Newman -- Keuls tests	34548
Newman	34548
Keuls tests	34555
Functional data from the rope locomotion-rating scale -LRB- deficit scores -RRB-	34568
Functional data	34568
the rope locomotion-rating scale -LRB- deficit scores -RRB-	34589
the rope locomotion-rating scale	34589
deficit scores	34623
nonparametric Kruskall -- Wallis ANOVA test	34660
nonparametric Kruskall	34660
Wallis ANOVA test	34683
Wallis ANOVA	34683
test	34696
The Pearson correlation test	34702
there	34763
possible relationships between different outcome parameters	34774
possible relationships	34774
different outcome parameters	34805
p 0.01	34883
All data incorporated in the analysis	34893
All data	34893
the analysis	34918
animals that survived the entire study	34950
animals	34950
the entire study	34972
Results Figure 1 .	34991
Results	34991
Figure 1	34999
In vitro analysis of AdV vector-mediated transgene expression .	35009
In vitro analysis	35009
AdV vector-mediated transgene expression	35030
A , Conditioned medium from uninfected and AdV-LacZ -LRB- controls -RRB- or neurotrophin-encoding AdV	35072
, Conditioned medium from uninfected and AdV-LacZ -LRB- controls -RRB-	35073
, Conditioned medium	35073
uninfected and AdV-LacZ -LRB- controls -RRB-	35099
uninfected	35099
AdV-LacZ -LRB- controls -RRB-	35114
AdV-LacZ	35114
controls	35124
OEG cultures -LRB- 10 5 cells -RRB-	35180
OEG cultures	35180
10 5 cells	35194
the presence of BDNF and NT-3	35223
the presence	35223
BDNF and NT-3	35239
ELISA techniques	35259
Bars	35277
averages SEM -LRB- n = 4 -RRB-	35291
averages SEM	35291
n	35305
4	35307
4 d after transduction	35314
4 d	35314
transduction	35324
low levels of BDNF -LRB- ≈ 0.5 ng -RRB-	35338
low levels of BDNF	35338
low levels	35338
BDNF	35352
≈ 0.5 ng	35358
≈	35358
0.5 ng	35359
medium taken from control OEG cultures over a 24 hr time period	35390
medium	35390
control OEG cultures over a 24 hr time period	35408
control OEG cultures	35408
a 24 hr time period	35434
NT-3	35463
N.D.	35488
Transduction of OEG cultures with neurotrophin-encoding AdV vectors	35495
Transduction	35495
OEG cultures with neurotrophin-encoding AdV vectors	35511
OEG cultures	35511
neurotrophin-encoding AdV vectors	35529
high levels of recombinant BDNF and NT-3 , secreted into the culture medium	35575
high levels	35575
recombinant BDNF and NT-3	35590
the culture medium	35631
a net rate of 43.8 ± 6.8 ng and 50.8 ± 3.7 ng/10	35653
a net rate	35653
43.8 ± 6.8 ng and 50.8 ± 3.7 ng/10	35667
43.8 ± 6.8 ng	35667
43.8 ±	35667
6.8 ng	35672
50.8 ± 3.7 ng/10	35683
50.8 ±	35683
3.7 ng/10	35688
^ 5 cells per day	35697
^ 5 cells	35697
day	35710
B -- E , Biological activity of AdV vector-derived BDNF and NT-3	35729
B	35729
E , Biological activity of AdV vector-derived BDNF and NT-3	35731
E , Biological activity	35731
AdV vector-derived BDNF and NT-3	35757
AdV vector-derived BDNF	35757
NT-3	35785
a 24 hr coculture experiment of transduced OEG and E14 DRG explants	35807
a 24 hr coculture experiment	35807
OEG and E14 DRG explants	35850
This	35876
visualization of the additional effect of transgenic neurotrophin expression	35889
visualization	35889
the additional effect of transgenic neurotrophin expression	35906
the additional effect	35906
transgenic neurotrophin expression	35931
the neurite outgrowthpromoting properties of OEG	35969
the neurite outgrowthpromoting properties	35969
OEG	36014
Similar moderate outgrowth of neurites	36019
Similar moderate outgrowth	36019
neurites	36049
DRG explants	36076
top of uninfected -LRB- B -RRB- or AdV-LacZ-transduced -LRB- C -RRB- OEG cultures	36103
top	36103
uninfected -LRB- B -RRB- or AdV-LacZ-transduced -LRB- C -RRB- OEG cultures	36110
uninfected -LRB- B -RRB-	36110
AdV-LacZ-transduced -LRB- C -RRB- OEG cultures	36129
C	36151
This	36168
AdV vector infection itself	36188
AdV vector infection	36188
the growth-promoting properties of these cells	36230
the growth-promoting properties	36230
these cells	36265
Robust neurite outgrowth	36278
DRG explants cocultured with OEG transducedwithanAdVvector - encodingBDNF -LRB- D -RRB- orNT-3 -LRB- E -RRB-	36321
DRG explants	36321
OEG transducedwithanAdVvector	36350
encodingBDNF -LRB- D -RRB- orNT-3 -LRB- E -RRB-	36381
encodingBDNF -LRB- D -RRB- orNT-3	36381
encodingBDNF -LRB- D -RRB-	36381
encodingBDNF	36381
D	36394
E	36404
ThisdemonstratesthatAdVvector-derived neurotrophins	36407
OEG in biologically active form	36478
OEG	36478
biologically active form	36485
these	36520
OEG	36537
neurite outgrowth	36574
culture	36595
Scale bar : -LRB- in E -RRB- B -- E , 1 mm .	36604
Scale bar : -LRB- in E -RRB- B	36604
Scale bar	36604
Scale	36604
bar	36610
E	36619
E , 1 mm	36624
E	36624
1 mm	36627
Figure 2 .	36634
Figure	36634
2	36641
In vivo analysis of AdV vector-mediated neurotrophin expression	36644
In vivo analysis	36644
AdV vector-mediated neurotrophin expression	36664
OEG	36722
implantation	36732
the lesioned spinal cord	36748
7 d after implantation	36777
7 d	36777
implantation	36787
many cells expressing high levels of BDNF and NT-3 mRNA	36801
many cells	36801
high levels of BDNF and NT-3 mRNA	36823
high levels	36823
BDNF and NT-3 mRNA	36838
the lesion area	36874
Animals implanted with uninfected or AdV-LacZ-transduced OEG -LRB- control implants -RRB-	36891
Animals	36891
uninfected or AdV-LacZ-transduced OEG	36914
control implants	36953
such neurotrophin mRNA expression at the injury site	36987
such neurotrophin mRNA expression	36987
the injury site	37024
Transgene-expressing cells	37041
the host spinal cord bridging the injury site	37094
the host spinal cord	37094
the injury site	37124
Histological analysis of adjacent sections	37141
Histological analysis	37141
adjacent sections	37166
these cells	37196
the confines of p75 NTR immunoreactivity , which identifies them as implanted OEG.Someadditional labeling for p75 NTR -LRB- Schwann cells -RRB- was found at the lateral edges of the spinal cord , at the level of the dorsal root -LRB- dr -RRB- entry zone -LRB- dashed line -RRB-	37229
the confines	37229
p75 NTR immunoreactivity , which identifies them as implanted OEG.Someadditional labeling for p75 NTR -LRB- Schwann cells -RRB- was found at the lateral edges of the spinal cord , at the level of the dorsal root -LRB- dr -RRB- entry zone -LRB- dashed line -RRB-	37245
p75 NTR immunoreactivity	37245
them	37288
OEG.Someadditional labeling for p75 NTR -LRB- Schwann cells -RRB-	37306
OEG.Someadditional labeling	37306
p75 NTR -LRB- Schwann cells -RRB-	37338
p75 NTR	37338
Schwann cells	37347
the lateral edges of the spinal cord	37375
the lateral edges	37375
the spinal cord	37396
the level of the dorsal root -LRB- dr -RRB- entry zone -LRB- dashed line -RRB-	37416
the level	37416
the dorsal root -LRB- dr -RRB- entry zone -LRB- dashed line -RRB-	37429
the dorsal root -LRB- dr -RRB- entry zone	37429
dorsal root -LRB- dr -RRB-	37433
dorsal root	37433
dr	37446
line	37469
Visualization of the developing glial scar	37476
Visualization	37476
the developing glial scar	37493
the vast majority of transgene-expressing cells	37531
the vast majority	37531
transgene-expressing cells	37552
the lesion center	37594
GFAP-positive reactive astrocytes	37630
Scale bar , 100µm .	37665
Scale bar	37665
100µm	37676
Figure 3 .	37684
Figure	37684
3	37691
Immunohistochemical characterization of the lesion area at 4 months after injury .	37694
Immunohistochemical characterization	37694
the lesion area	37734
4 months	37753
injury	37768
A , B , Staining for fibronectin -LRB- green -RRB-	37776
A , B , Staining for fibronectin	37776
A , B , Staining	37776
B	37779
fibronectin	37795
a marker	37827
scar-associated meningeal cells and fibroblasts in the lesion area	37849
scar-associated meningeal cells and fibroblasts	37849
the lesion area	37900
immunohistochemistry for p75 NTR -LRB- red -RRB-	37934
immunohistochemistry	37934
p75 NTR -LRB- red -RRB-	37959
p75 NTR	37959
red	37968
a general antigenic marker for implanted OEG	37976
a general antigenic marker	37976
implanted OEG	38007
A , In unimplanted controls , fibronectin	38022
unimplanted controls	38028
the lesion area	38086
only little immunoreactivity for p75 NTR	38107
only little immunoreactivity	38107
p75 NTR	38140
Fibronectin-positive cells	38149
the lesion gap	38195
virtually no cystic cavity formation	38215
Most of the p75 NTR-stained cells	38266
Most	38266
the p75 NTR-stained cells	38274
typical bipolar Schwann cell morphology -LRB- inset is a higher magnification of the outlined area -RRB- that may have migrated into the lesion area from the dorsal root	38310
typical bipolar Schwann cell morphology	38310
inset	38351
a higher magnification of the outlined area	38360
a higher magnification	38360
the outlined area	38386
the lesion area	38433
the dorsal root	38454
B , Abundant and elevated p75 NTR immunoreactivity	38471
B	38471
Abundant	38474
elevated p75 NTR immunoreactivity	38487
the lesion area of all OEG implanted animals , indicating that apart from the endogenous Schwann cells present , grafted cells did survive in the lesioned spinal cord	38534
the lesion area	38534
all OEG implanted animals , indicating that apart from the endogenous Schwann cells present , grafted cells did survive in the lesioned spinal cord	38553
all OEG	38553
animals	38571
the endogenous Schwann cells present , grafted	38607
the endogenous Schwann cells	38607
cells	38653
the lesioned spinal cord	38674
C , D , Representative confocal microscope images of the lesion center of an unimplanted control and typical OEG-implanted rat , respectively , at higher magnification .	38700
C	38700
D , Representative confocal microscope images of the lesion center of an unimplanted control and typical OEG-implanted rat , respectively	38703
D	38703
Representative confocal microscope images of the lesion center of an unimplanted control and typical OEG-implanted rat , respectively	38706
Representative confocal microscope images	38706
the lesion center of an unimplanted control and typical OEG-implanted rat , respectively	38751
the lesion center of an unimplanted control	38751
the lesion center	38751
an unimplanted control	38772
typical OEG-implanted rat , respectively	38799
typical OEG-implanted rat	38799
higher magnification	38843
Immunohistochemistry for p75 NTR -LRB- red -RRB-	38865
Immunohistochemistry for p75 NTR	38865
Immunohistochemistry	38865
p75 NTR	38890
red	38899
staining	38922
neurofilament -LRB- green -RRB- to visualize all axons present in this area	38935
all axons	38970
this area	38991
C , Few axons	39002
the lesion center of unimplanted controls -LRB- arrows -RRB- , some of them displaying typical end bulb-like structures -LRB- arrowhead -RRB-	39032
the lesion center	39032
unimplanted controls -LRB- arrows -RRB- , some of them displaying typical end bulb-like structures -LRB- arrowhead -RRB-	39053
unimplanted controls -LRB- arrows -RRB-	39053
unimplanted controls	39053
arrows	39075
some of them displaying typical end bulb-like structures -LRB- arrowhead -RRB-	39084
some	39084
them	39092
typical end bulb-like structures -LRB- arrowhead -RRB-	39108
typical end bulb-like structures	39108
arrowhead	39142
D	39154
all OEG-implanted rats	39160
numerous NF-positive axons	39184
the graft area	39225
bipolar p75 NTR-positive cells -LRB- arrows -RRB-	39261
bipolar p75 NTR-positive cells	39261
arrows	39293
This	39302
several unidentified populations of spinal axons	39322
several unidentified populations	39322
spinal axons	39358
the OEG implantation site	39403
Scale bars	39430
Scale	39430
bars	39436
A , B , 100µm	39442
A	39442
B	39445
100µm	39448
25µm	39461
Figure 4 .	39468
Figure	39468
4	39475
The regenerative response of lesioned RST axons to different types of AdV vector-transduced OEG implants 4 months after injury .	39478
The regenerative response	39478
lesioned RST axons	39507
different types of AdV vector-transduced OEG implants 4 months	39529
different types	39529
AdV vector-transduced OEG implants	39548
4 months	39583
injury	39598
All experimental animals	39606
BDA , which was iontophoretically applied 2 weeks before perfusion	39648
BDA	39648
2 weeks	39689
perfusion	39704
Representative photomicrographs of horizontal sections through the cervical spinal cord show anterograde BDA-traced RST axons -LRB- black -RRB- and reactive GFAP-positive astrocytes -LRB- brown -RRB- at the lesion and OEG implantation site .	39715
Representative photomicrographs	39715
horizontal sections	39750
the cervical spinal cord show anterograde BDA-traced RST axons -LRB- black -RRB- and reactive GFAP-positive astrocytes -LRB- brown -RRB-	39778
the cervical spinal cord show	39778
BDA-traced RST axons -LRB- black -RRB- and reactive GFAP-positive astrocytes -LRB- brown -RRB-	39820
BDA-traced RST axons	39820
reactive GFAP-positive astrocytes	39853
brown	39888
the lesion and OEG implantation site	39898
DAB double staining	39936
cresyl violet counterstaining -LRB- blue -RRB-	39974
cresyl violet counterstaining	39974
blue	40005
better visualize tissue cytoarchitecture	40014
better	40014
tissue cytoarchitecture	40031
all cases	40059
the injury	40099
lines	40123
graft	40138
host interfaces	40145
A , C , Traced RST axons proximal to the lesion in an unimplanted control animal .	40162
A , C , Traced RST axons proximal to the lesion in an unimplanted control animal	40162
A , C ,	40162
C	40165
RST axons	40175
the lesion in an unimplanted control animal	40197
the lesion	40197
an unimplanted control animal	40211
C , Higher magnification of the outlined area in A , showing that RST axons -LRB- arrows -RRB- did not regenerate into the lesion area -LRB- asterisk -RRB- , and all stopped at the proximal border of the scar delineated by GFAP-positive astrocytes .	40242
C	40242
Higher magnification of the outlined area in A , showing that RST axons -LRB- arrows -RRB- did not regenerate into the lesion area -LRB- asterisk -RRB- , and all stopped at the proximal border of the scar delineated by GFAP-positive astrocytes	40245
Higher magnification	40245
the outlined area in A	40269
the outlined area	40269
A	40290
RST axons -LRB- arrows -RRB-	40306
RST axons	40306
arrows	40317
the lesion area -LRB- asterisk -RRB-	40349
the lesion area	40349
asterisk	40366
all	40381
the proximal border of the scar delineated by GFAP-positive astrocytes	40396
the proximal border	40396
the scar delineated by GFAP-positive astrocytes	40419
the scar	40419
GFAP-positive astrocytes	40442
B , Termination of lesioned BDA-traced RST axons at the lesion site after implantation of AdV-LacZ-transduced OEG .	40468
B	40468
Termination of lesioned BDA-traced RST axons at the lesion site after implantation of AdV-LacZ-transduced OEG	40471
Termination	40471
lesioned BDA-traced RST axons at the lesion site after implantation of AdV-LacZ-transduced OEG	40486
lesioned BDA-traced RST axons	40486
the lesion site after implantation of AdV-LacZ-transduced OEG	40519
the lesion site	40519
implantation of AdV-LacZ-transduced OEG	40541
implantation	40541
AdV-LacZ-transduced OEG	40557
No sprouting of the RST into the graft and lesion area	40582
No sprouting	40582
the RST into the graft and lesion area	40598
the RST	40598
the graft and lesion area	40611
D , E , Higher magnifications of the corresponding areas outlined in B , showing end bulb-like axon endings at the proximal graft -- host boundary -LRB- arrows -RRB- .	40651
D , E	40651
D	40651
E	40654
Higher magnifications of the corresponding areas outlined in B	40657
Higher magnifications	40657
the corresponding areas outlined in B	40682
the corresponding areas	40682
B	40718
end bulb-like axon endings	40729
the proximal graft -- host boundary -LRB- arrows -RRB-	40759
the proximal graft	40759
host boundary	40779
arrows	40794
Similar distribution patterns of traced RST axons	40803
Similar distribution patterns	40803
traced RST axons	40836
OEG	40869
no or AdV-NT-3 vector	40898
no	40898
AdV-NT-3 vector	40904
implantation	40927
F -- J , RST axon sprouting in representative animals after implantation of AdV-BDNF-transduced OEG .	40941
F	40941
J , RST axon sprouting in representative animals after implantation of AdV-BDNF-transduced OEG	40943
J	40943
RST axon sprouting in representative animals after implantation of AdV-BDNF-transduced OEG	40946
RST axon	40946
representative animals	40968
implantation of AdV-BDNF-transduced OEG	40997
implantation	40997
AdV-BDNF-transduced OEG	41013
F , RST axon regeneration into the graft	41038
F , RST axon regeneration	41038
the graft	41068
The dashed line	41092
the rostral graft -- host interface as determined using dark-field microscopy -LRB- inset ; asterisk , blood vessel ; wm , white matter -RRB-	41118
the rostral graft -- host interface as	41118
the rostral graft	41118
host interface as	41137
host interface	41137
dark-field microscopy	41172
asterisk , blood vessel ; wm , white matter	41202
asterisk	41202
blood vessel ; wm	41212
blood vessel	41212
wm	41226
white matter	41230
the graft -- host interface -LRB- arrows -RRB- with some axons present in the central core of the lesion and implantation site -LRB- arrowhead -RRB-	41292
the graft	41292
host interface -LRB- arrows -RRB- with some axons	41303
host interface -LRB- arrows -RRB-	41303
host interface	41303
arrows	41319
some axons	41332
the central core of the lesion and implantation site	41354
the central core	41354
the lesion and implantation site	41374
arrowhead	41408
G , Traced RST axons deeper in the graft -LRB- arrows -RRB- .	41420
G	41420
RST axons	41430
the graft -LRB- arrows -RRB-	41450
the graft	41450
arrows	41461
H , BDA-labeled RST axons at the caudal graft -- host interface .	41469
H , BDA-labeled RST axons at the caudal graft	41469
H	41469
BDA-labeled RST axons at the caudal graft	41472
BDA-labeled RST axons	41472
the caudal graft	41497
host interface	41515
I , Higher magnification of the outlined area in G , showing undirectional growth of RST axons -LRB- arrow -RRB- .	41531
I	41531
Higher magnification of the outlined area in G , showing undirectional growth of RST axons -LRB- arrow -RRB-	41534
Higher magnification	41534
the outlined area in G	41558
the outlined area	41558
G	41579
undirectional growth of RST axons -LRB- arrow -RRB-	41590
undirectional growth	41590
RST axons -LRB- arrow -RRB-	41614
RST axons	41614
arrow	41625
J , Higher magnification of corresponding area in H. Few axons	41633
J	41633
Higher magnification of corresponding area in H. Few axons	41636
Higher magnification	41636
corresponding area in H. Few axons	41660
corresponding area	41660
H. Few axons	41682
the graft	41715
the host spinal cord -LRB- arrow -RRB-	41750
the host spinal cord	41750
arrow	41772
Scale bars : A , 220µm ; B , C , F -- H , 92µm ; D , E , 36µm ; I , J , 23µm .	41780
Scale bars	41780
A , 220µm	41792
A	41792
220µm	41795
B , C , F	41802
B	41802
C	41805
F	41808
H , 92µm	41810
H	41810
92µm	41813
D , E , 36µm	41819
D	41819
E	41822
36µm	41825
I , J , 23µm	41831
I	41831
J	41834
23µm	41837
Figure 5 .	41844
Figure	41844
5	41851
Graphic representation of the regenerative response of BDA-traced RST axons after implantation of AdV	41854
Graphic representation	41854
the regenerative response of BDA-traced RST axons after implantation of AdV	41880
the regenerative response	41880
BDA-traced RST axons after implantation of AdV	41909
BDA-traced RST axons	41909
implantation of AdV	41936
implantation	41936
AdV	41952
OEG	41973
4 months	41977
injury	41992
Top , Schematic representation of spinal cord lesion model and OEG injection sites .	42000
Top , Schematic representation	42000
spinal cord lesion model and OEG injection sites	42033
RN , Red nucleus .	42083
RN	42083
Red nucleus	42087
Camera lucida drawings made of representative animals from each experimental group	42100
Camera lucida drawings	42100
representative animals	42131
each experimental group	42159
the distribution pattern of BDA-traced RST axons -LRB- black -RRB- and their collaterals in the spinal cord gray matter -LRB- light gray area -RRB- at the injury site -LRB- gray area -RRB-	42199
the distribution pattern of BDA-traced RST axons -LRB- black -RRB-	42199
the distribution pattern	42199
BDA-traced RST axons -LRB- black -RRB-	42227
BDA-traced RST axons	42227
their collaterals in the spinal cord gray matter -LRB- light gray area -RRB- at the injury site -LRB- gray area -RRB-	42260
their collaterals	42260
the spinal cord gray matter -LRB- light gray area -RRB- at the injury site -LRB- gray area -RRB-	42281
the spinal cord gray matter -LRB- light gray area -RRB-	42281
the spinal cord gray matter	42281
light gray area	42310
the injury site -LRB- gray area -RRB-	42330
the injury site	42330
gray area	42347
The latter	42359
both scar-associated cells	42380
OEG	42421
NTs , BDNF plus NT-3 .	42426
NTs	42426
BDNF plus NT-3	42431
BDNF	42431
NT-3	42441
Scale bar , 450µm .	42447
Scale bar	42447
450µm	42458
Figure 6 .	42466
Figure	42466
6	42473
Quantitative analysis of the regenerative response of lesioned RST axons after implantation of different types of AdV vector-transduced OEG .	42476
Quantitative analysis	42476
the regenerative response of lesioned RST axons	42501
the regenerative response	42501
lesioned RST axons	42530
implantation	42555
different types of AdV vector-transduced OEG	42571
different types	42571
AdV vector-transduced OEG	42590
variability in RST-tracing efficiency	42635
variability	42635
RST-tracing efficiency	42650
fiber counts at 3 mm proximal to the lesion	42674
fiber counts	42674
3 mm proximal to the lesion	42690
3 mm	42690
the lesion	42707
100 %	42730
all other points calculated	42740
all other points	42740
relative percentages	42780
Data	42802
averages ± SEM	42824
averages	42824
SEM	42834
The shaded area	42839
the outer confines of the distribution pattern of BDA-traced RST axon	42866
the outer confines	42866
the distribution pattern of BDA-traced RST axon	42888
the distribution pattern	42888
BDA-traced RST axon	42916
the control groups	42946
`` lesion only '' and uninfected or AdV-LacZ-transduced OEG , respectively	42966
`` lesion only '' and uninfected or AdV-LacZ-transduced OEG	42966
lesion only	42967
uninfected or AdV-LacZ-transduced OEG	42984
Top	43038
No statistically significant differences in the number of RST fibers	43049
No statistically significant differences	43049
the number of RST fibers	43093
the number	43093
RST fibers	43107
implantation of uninfected OEG -LRB- p = 0.52 -RRB- or AdV-LacZ-transduced OEG -LRB- p = 0.12 -RRB-	43135
implantation	43135
uninfected OEG -LRB- p = 0.52 -RRB- or AdV-LacZ-transduced OEG -LRB- p = 0.12 -RRB-	43151
uninfected OEG	43151
p	43168
0.52	43170
AdV-LacZ-transduced OEG	43179
p = 0.12	43205
p =	43205
0.12	43207
Top	43228
Implantation of AdV-NT-3-transduced OEG	43240
Implantation	43240
AdV-NT-3-transduced OEG	43256
a regenerative response of lesioned RST axons	43295
a regenerative response	43295
lesioned RST axons	43322
animals that received either no implant or a graft of uninfected or AdV-LacZ-transduced OEG , respectively -LRB- controls ; p > 0.28 -RRB-	43355
animals	43355
no implant or a graft of uninfected or AdV-LacZ-transduced OEG , respectively	43384
no	43384
a graft of uninfected or AdV-LacZ-transduced OEG , respectively	43398
a graft	43398
uninfected or AdV-LacZ-transduced OEG , respectively	43409
uninfected or AdV-LacZ-transduced OEG	43409
controls ; p > 0.28	43462
controls	43462
p > 0.28	43472
p >	43472
p	43472
0.28	43474
Bottom , Left , Right , Quantification of the regenerative response of RST axons after implantation of AdV-BDNF-transduced OEG or OEG	43481
Bottom	43481
Quantification of the regenerative response of RST axons after implantation of AdV-BDNF-transduced OEG or OEG	43502
Quantification	43502
the regenerative response of RST axons after implantation of AdV-BDNF-transduced OEG or OEG	43520
the regenerative response	43520
RST axons after implantation of AdV-BDNF-transduced OEG or OEG	43549
RST axons	43549
implantation of AdV-BDNF-transduced OEG or OEG	43565
implantation	43565
AdV-BDNF-transduced OEG or OEG	43581
both BDNF and NT-3-encoding AdV vectors	43628
BDNF	43633
NT-3-encoding AdV vectors	43642
RST axon counts	43669
RST axon	43669
these grafts	43699
axonal dieback	43722
RST axons	43773
the lesion area -LRB- p < 0.0001 -RRB-	43788
the lesion area	43788
p < 0.0001	43806
p	43806
< 0.0001	43807
<	43807
0.0001	43808
No significant differences	43817
these two groups -LRB- p = 0.33 -RRB-	43863
these two groups	43863
p	43882
0.33	43884
coexpression of BDNF and NT-3	43907
coexpression	43907
BDNF and NT-3	43923
no synergistic	43941
effect	43973
RST outgrowth	43983
Figure 7 .	43999
Figure	43999
7	44006
OEG implants	44009
lesion size	44029
implantation in the lesioned rat spinal cord	44047
implantation	44047
the lesioned rat spinal cord	44063
A , Example of lesion size determination in an OEG	44093
A , Example of lesion size determination	44093
Example	44096
lesion	44107
an OEG	44136
animal	44153
dark-field microscopy	44166
Top , Adiscontinuity of normal spinal cord cytoarchitecture and a high density of small cells that invaded the injury site clearly defined the borders of the damaged area .	44189
Top	44189
Adiscontinuity of normal spinal cord cytoarchitecture and a high density of small cells that invaded the injury site clearly defined the borders of the damaged area	44193
Adiscontinuity	44193
normal spinal cord cytoarchitecture and a high density of small cells	44211
normal spinal cord cytoarchitecture	44211
a high density of small cells	44251
a high density	44251
small cells	44269
the injury site	44294
the borders of the damaged area	44326
the borders	44326
the damaged area	44341
Bottom , Computerized image analysis picture showing the outlined damaged -LRB- shaded -RRB- area to determine lesion size .	44359
Bottom	44359
Computerized image analysis picture showing the outlined damaged -LRB- shaded -RRB- area to determine lesion size	44367
Computerized image analysis picture	44367
the outlined damaged -LRB- shaded -RRB- area to determine lesion size	44411
the	44411
shaded	44433
area to determine lesion size	44441
lesion size	44459
gm , Gray matter ; wm , white matter .	44472
gm , Gray matter	44472
gm	44472
Gray matter	44476
wm , white matter	44489
wm	44489
white matter	44493
B , Graphic representation showing lesion volumes in cubic millimeters -LRB- average ± SEM -RRB- .	44507
B	44507
Graphic representation showing lesion volumes in cubic millimeters -LRB- average ± SEM -RRB-	44510
Graphic representation	44510
lesion volumes	44541
cubic millimeters -LRB- average ± SEM -RRB-	44559
cubic millimeters	44559
average ± SEM	44578
A consistent trend toward smaller lesion volumes	44594
A consistent trend	44594
smaller lesion volumes	44620
all OEG-implanted animals	44656
Significant reduction in lesion size	44683
Significant reduction	44683
lesion size	44708
implantation of AdV-BDNF	44741
implantation	44741
AdV-BDNF	44757
AdV-NT-3	44768
AdV-BDNF	44782
AdV-NT-3-transduced OEG , respectively	44796
AdV-NT-3-transduced OEG	44796
Asterisks	44835
statistically significant differences -LRB- p < 0.05 -RRB-	44854
statistically significant differences	44854
p < 0.05	44894
p	44894
< 0.05	44897
<	44897
0.05	44899
lesioned unimplanted controls	44910
Figure 8 .	44942
Figure	44942
8	44949
Four examples of representative rubrospinal MEP recordings from an intact and lesioned control and after AdV vector-transduced OEG implantation .	44952
Four examples	44952
representative rubrospinal MEP recordings	44969
an intact and lesioned control	45016
AdV vector-transduced OEG implantation	45057
unilateral transection of the dorsolateral funiculus	45103
unilateral transection	45103
the dorsolateral funiculus	45129
a significant decrease -LRB- p < 0.001 -RRB- in the amplitude of the first peak	45157
a significant decrease -LRB- p < 0.001 -RRB-	45157
a significant decrease	45157
p < 0.001	45182
p	45182
< 0.001	45183
<	45183
0.001	45185
the amplitude of the first peak	45195
the amplitude	45195
the first peak	45212
all groups	45243
age-matched unlesioned control animals -LRB- arrow -RRB-	45268
age-matched unlesioned control animals	45268
arrow	45308
No treatment-based statistical differences in amplitude of this peak	45316
No treatment-based statistical differences	45316
amplitude of this peak	45362
amplitude	45362
this peak	45375
experimental groups , which indicates the absence of robust and functional RST regeneration	45405
experimental groups	45405
the absence of robust and functional RST regeneration	45442
the absence	45442
robust and functional RST regeneration	45457
Calibration : 10µV , 1 msec .	45497
Calibration	45497
10µV , 1 msec	45510
10µV	45510
1 msec	45516
Figure 9 .	45525
Figure	45525
9	45532
OEG implants	45535
recovery of hindlimb function	45556
recovery	45556
hindlimb function	45568
horizontal rope walking	45593
A , Photographs captured from video recordings showing experimental animals crossing the rope 4 months after injury .	45618
A	45618
Photographs captured from video recordings showing experimental animals crossing the rope 4 months after injury	45621
Photographs	45621
video recordings showing experimental animals crossing the rope 4 months after injury	45647
video recordings	45647
experimental animals	45672
the rope	45702
4 months	45711
injury	45726
Top , Typical example of a slip and fall from the rope	45734
Top , Typical example	45734
a slip and fall from the rope	45758
a slip and fall	45758
the rope	45779
unimplanted lesioned controls	45811
Bottom , All OEG-implanted rats	45842
Bottom	45842
All OEG-implanted rats	45850
better functional performance -LRB- fewer slips and falls -RRB- during horizontal rope locomotion	45877
better functional performance -LRB- fewer slips and falls -RRB-	45877
better functional performance	45877
fewer slips and falls	45908
fewer	45908
horizontal rope locomotion	45938
addition	45969
implantation of neurotrophin-encoding AdV	45979
implantation	45979
neurotrophin-encoding AdV	45995
OEG	46038
better general body posture during task performance	46054
better general body posture	46054
task performance	46089
This	46107
better paw placement under the body and elevated trunk position and tail position -LRB- bottom right -RRB-	46135
better paw placement	46135
the body and elevated trunk position and tail position -LRB- bottom right -RRB-	46162
the body	46162
elevated trunk position and tail position -LRB- bottom right -RRB-	46175
elevated trunk position and tail position	46175
bottom right	46218
other OEG-implanted rats -LRB- bottom left -RRB-	46246
other OEG-implanted rats	46246
bottom left	46272
bottom	46272
B , Mean deficit scores	46286
B	46286
Mean deficit scores	46289
SEM	46310
each experimental group	46333
up to 16 weeks	46357
injury	46378
Unilateral transection of the dorsolateral funiculus	46386
Unilateral transection	46386
the dorsolateral funiculus	46412
severe functional impairments of the ipsilateral hindlimb 7 d	46451
severe functional impairments	46451
the ipsilateral hindlimb 7 d	46484
the ipsilateral hindlimb	46484
injury	46519
Monitoring of the left -LRB- ipsilateral -RRB- hindlimb during horizontal rope locomotion	46527
Monitoring	46527
the left -LRB- ipsilateral -RRB- hindlimb during horizontal rope locomotion	46541
the left -LRB- ipsilateral -RRB- hindlimb	46541
ipsilateral	46551
horizontal rope locomotion	46580
recovery of function	46621
recovery	46621
function	46633
all OEG-implanted animal groups	46654
the first postoperative weeks	46693
4 weeks	46729
hardly any improvement in deficit score	46745
hardly any improvement	46745
deficit score	46771
a significant main treatment effect	46800
all OEG-implanted animal groups	46851
p	46885
≤ 0.0002	46886
No differences	46896
uninfected and AdV-LacZ-transduced OEG implanted rats -LRB- p = 0.99 -RRB-	46930
uninfected and AdV-LacZ-transduced OEG	46930
rats -LRB- p = 0.99 -RRB-	46979
rats	46979
p	46986
0.99	46990
AdV vector-directed neurotrophin expression	46997
AdV	46997
vector-directed neurotrophin expression	47001
a significantly enhanced main effect of the treatment -LRB- p < 0.00002 -RRB-	47053
a significantly enhanced main effect	47053
the treatment -LRB- p < 0.00002 -RRB-	47093
the treatment	47093
p < 0.00002	47109
p	47109
< 0.00002	47111
<	47111
0.00002	47112
all other groups	47135
no differences	47161
these groups -LRB- p > 0.53 -RRB-	47198
these groups	47198
p > 0.53	47213
p	47213
> 0.53	47214
>	47214
0.53	47215
C , Calculated total error/step ratios -LRB- average ± SEM -RRB- 4 months after implantation .	47222
C	47222
total error/step ratios -LRB- average ± SEM -RRB-	47236
total error/step ratios	47236
average ± SEM	47261
4 months	47275
implantation	47290
A statistically significant reduction in error score	47304
A statistically significant reduction	47304
error score	47345
asterisk ; fewer	47358
asterisk	47358
fewer	47368
p <	47391
p	47391
0.0002	47394
all OEG-implanted rats	47415
unimplanted lesioned controls	47452
no difference	47490
uninfected and AdV-LacZ-transduced OEG implants -LRB- p = 0.57 -RRB-	47522
uninfected and AdV-LacZ-transduced OEG implants	47522
p	47572
0.57	47574
Implantation of neurotrophin-encoding AdV vector-transduced OEG	47581
Implantation	47581
neurotrophin-encoding AdV vector-transduced OEG	47597
a further improvement of hindlimb function -LRB- fewer slips and no falls -RRB- that was statistically significant after implantation of AdV-NT-3 -LRB- p = 0.02 -RRB- or AdV-BDNF plus NT-3 -LRB- p = 0.009 ; double asterisks -RRB- - transduced OEG	47657
a further improvement	47657
hindlimb function -LRB- fewer slips and no falls -RRB- that was statistically significant after implantation of AdV-NT-3 -LRB- p = 0.02 -RRB- or AdV-BDNF plus NT-3 -LRB- p = 0.009 ; double asterisks -RRB- - transduced OEG	47682
hindlimb function	47682
fewer slips and no falls	47701
fewer	47701
implantation of AdV-NT-3 -LRB- p = 0.02 -RRB- or AdV-BDNF plus NT-3 -LRB- p = 0.009 ; double asterisks -RRB- - transduced OEG	47768
implantation	47768
AdV-NT-3 -LRB- p = 0.02 -RRB- or AdV-BDNF plus NT-3 -LRB- p = 0.009 ; double asterisks -RRB- -	47784
AdV-NT-3 -LRB- p = 0.02 -RRB-	47784
AdV-NT-3	47784
p	47795
0.02	47797
AdV-BDNF plus NT-3 -LRB- p = 0.009 ; double asterisks -RRB-	47806
AdV-BDNF	47806
NT-3	47820
p	47827
= 0.009 ; double asterisks	47828
= 0.009	47828
double asterisks	47836
OEG	47865
No statistical differences	47870
these groups -LRB- p > 0.64 -RRB-	47919
these groups	47919
p > 0.64	47934
p	47934
> 0.64	47936
>	47936
0.64	47938
D , Functional performance of the impaired hindlimb	47945
D	47945
Functional performance of the impaired hindlimb	47948
Functional performance	47948
the impaired hindlimb	47974
lesion size	48012
Scatter graph of calculated total error/step ratios plotted against accompanying lesion volumes	48025
Scatter graph	48025
calculated total error/step ratios plotted against accompanying lesion volumes	48042
calculated total error/step ratios	48042
accompanying lesion volumes	48093
the existence of a positive correlation between hindlimb function and lesion size	48127
the existence	48127
a positive correlation between hindlimb function and lesion size	48144
a positive correlation	48144
hindlimb function and lesion size	48175
Pearson 's correlation test	48226
Pearson 's	48226
In vitro analysis of transgenic neurotrophin expression Transduction of primary p75NTR-purified OEG cultures with first-generation E1-deleted adenoviral vectors	48255
In vitro analysis	48255
transgenic neurotrophin expression Transduction of primary p75NTR-purified OEG cultures with first-generation E1-deleted adenoviral vectors	48276
transgenic neurotrophin expression Transduction	48276
primary p75NTR-purified OEG cultures with first-generation E1-deleted adenoviral vectors	48327
primary p75NTR-purified OEG cultures	48327
first-generation E1-deleted adenoviral vectors	48369
high levels of transgene expression	48428
high levels	48428
transgene expression	48443
many cells	48467
determined by in situ hybridization at 3 d after infection -LRB- data not shown -RRB-	48481
determined by in situ hybridization	48481
3 d after infection -LRB- data not shown -RRB-	48520
3 d	48520
infection	48530
data not shown	48541
data	48541
Numerous cells	48558
high levels of betta-gal , BDNF , or NT-3 mRNA	48583
high levels	48583
betta-gal , BDNF , or NT-3 mRNA	48598
signs of toxicity or cytopathological effects	48651
signs	48651
toxicity or cytopathological effects	48660
No staining for any of the transgenes	48698
No staining	48698
any of the transgenes	48714
any	48714
the transgenes	48721
uninfected OEG that served as control cultures or after hybridization with sense probe	48752
uninfected OEG	48752
control cultures	48782
hybridization	48808
sense probe	48827
Conditioned medium from transduced OEG cultures	48840
the presence of neurotrophins BDNF and NT-3 using an ELISA assay 4 d after transduction with AdV vectors -LRB- Fig. 1A -RRB-	48905
the presence	48905
neurotrophins BDNF and NT-3 using an ELISA assay 4 d after transduction with AdV vectors -LRB- Fig. 1A -RRB-	48921
neurotrophins BDNF and NT-3	48921
an ELISA assay 4 d	48955
transduction with AdV vectors -LRB- Fig. 1A -RRB-	48980
transduction	48980
AdV vectors -LRB- Fig. 1A -RRB-	48998
AdV vectors	48998
Fig. 1A	49011
Low levels of BDNF	49021
Low levels	49021
BDNF	49035
medium samples -LRB- n = 4 -RRB- taken from control -LRB- 0.45 ± 0.17 ng/105 cells per day -RRB- or AdVLacZ - transduced OEG cultures -LRB- 0.57 ± 0.13 ng/105 cells per day -RRB- , whereas NT-3 was not detectable	49057
medium samples	49057
n	49073
4	49077
control -LRB- 0.45 ± 0.17 ng/105 cells per day -RRB- or AdVLacZ	49091
control -LRB- 0.45 ± 0.17 ng/105 cells per day -RRB-	49091
control	49091
0.45 ± 0.17 ng/105 cells per day	49100
0.45 ± 0.17 ng/105 cells	49100
0.45	49100
0.17 ng/105 cells	49107
day	49129
AdVLacZ	49137
OEG cultures -LRB- 0.57 ± 0.13 ng/105 cells per day -RRB-	49157
OEG cultures	49157
0.57 ± 0.13 ng/105 cells per day	49171
0.57 ± 0.13 ng/105 cells	49171
0.57	49171
0.13 ng/105 cells	49178
day	49200
NT-3	49214
infection with AdVBDNF	49245
infection	49245
AdVBDNF	49260
an ≈	49269
the levels of BDNF -LRB- 43.8 ± 6.8 ng -RRB- secreted from transduced OEG was observed	49294
the levels	49294
BDNF -LRB- 43.8 ± 6.8 ng -RRB- secreted from transduced OEG was observed	49308
BDNF	49308
43.8 ± 6.8 ng	49314
43.8 ±	49314
6.8 ng	49321
OEG was observed	49354
OEG	49354
ELISA analysis of medium samples taken from AdV-NT-3-transduced OEG cultures	49372
ELISA analysis	49372
medium samples taken from AdV-NT-3-transduced OEG cultures	49390
medium samples	49390
AdV-NT-3-transduced OEG cultures	49416
at least 50.8 ± 3.7 ng of recombinant NT-3	49463
at least 50.8 ± 3.7 ng	49463
recombinant NT-3	49487
105 cells per day	49522
105 cells	49522
day	49536
These results	49541
the time-point of implantation	49573
the time-point	49573
implantation	49591
high amounts of recombinant neurotrophin	49605
high amounts	49605
recombinant neurotrophin	49621
OEG transduced with an AdV vector-encoding BDNF or NT-3 as compared with controls	49665
OEG	49665
an AdV	49685
vector-encoding BDNF or NT-3	49692
controls	49738
Biological activity of AdV	49748
Biological activity	49748
AdV	49771
BDNF and NT-3	49789
a coculture experiment	49823
this	49851
E14 DRG explants -LRB- n = 12 -RRB-	49857
E14 DRG explants	49857
n	49875
12	49879
top of an AdV	49902
top	49902
an AdV	49909
monolayer of OEG	49933
monolayer	49933
OEG	49946
the effect of transgenic neurotrophic factor production	49963
the effect	49963
transgenic neurotrophic factor production	49977
neurite outgrowth	50054
24 hr after the initial plating	50072
24 hr	50072
the initial plating	50084
Moderate extensions of neurites	50105
Moderate extensions	50105
neurites	50128
E14 DRG explants	50156
uninfected or AdV-LacZ-transduced OEG -LRB- Fig. 1B , C -RRB-	50194
uninfected or AdV-LacZ-transduced OEG	50194
Fig. 1B , C	50233
Fig. 1B	50233
C	50241
No visible differences in radial neurite outgrowth	50245
No visible differences	50245
radial neurite outgrowth	50271
these groups	50318
AdV vector infection	50348
the growthsupporting properties of OEG	50392
the growthsupporting properties	50392
OEG	50427
A robust outgrowth of neurites from DRG explants	50432
A robust outgrowth	50432
neurites from DRG explants	50454
neurites	50454
DRG explants	50468
OEG monolayers	50496
an AdV vector-encoding BDNF or NT-3 -LRB- Fig. 1D , E -RRB-	50532
an AdV vector-encoding BDNF	50532
NT-3 -LRB- Fig. 1D , E -RRB-	50563
NT-3	50563
Fig. 1D , E	50569
Fig. 1D	50569
E	50577
These results	50581
AdV vector-derived neurotrophins	50612
recombinant BDNF and NT-3	50687
recombinant BDNF	50687
NT-3	50708
OEG	50741
ELISA	50768
In vivo analysis of transgene expression	50775
In vivo analysis	50775
transgene expression	50795
7 d	50819
implantation	50829
transgene expression in OEG implants	50843
transgene expression	50843
OEG implants	50867
in situ hybridization and immunohistochemical characterization	50896
in situ hybridization	50896
hybridization	50904
immunohistochemical characterization	50922
the lesion area -LRB- Fig. 2 -RRB-	50962
the lesion area	50962
Fig. 2	50979
Numerous cells displaying typical bipolar OEG morphology	50988
Numerous cells	50988
typical bipolar OEG morphology	51014
the lesion area expressing high levels of BDNF or NT-3 mRNA	51062
the lesion area	51062
high levels of BDNF or NT-3 mRNA	51089
high levels	51089
BDNF or NT-3 mRNA	51104
No such staining	51123
unimplanted animals	51155
implantation of AdV-LacZtransduced OEG -LRB- data not shown -RRB-	51184
implantation	51184
AdV-LacZtransduced OEG	51200
data not shown	51224
data	51224
the identity of BDNF - and NT-3	51254
the identity	51254
BDNF - and NT-3	51270
cells	51297
adjacent sections	51304
the presence of Hoechstlabeled cells and immunoreactivity	51340
the presence	51340
Hoechstlabeled cells and immunoreactivity	51356
p75NTR , which is a marker for OEG	51402
p75NTR	51402
a marker for OEG	51419
a marker	51419
OEG	51432
No BDNF - or NT-3-expressing cells	51437
No BDNF	51437
NT-3-expressing cells	51449
the confines of p75NTR immunoreactivity and Hoechst distribution pattern	51492
the confines	51492
p75NTR immunoreactivity and Hoechst distribution pattern	51508
p75NTR immunoreactivity	51508
Hoechst distribution pattern	51536
them	51578
OEG	51602
The vast majority of BDNFand NT-3-positive cells	51607
The vast majority	51607
BDNFand NT-3-positive cells	51628
the inner core of the lesion	51672
the inner core	51672
the lesion	51690
the injury site	51711
GFAP staining that was used to visualize the developing glial scar	51744
GFAP staining	51744
the developing glial scar	51785
Some additional p75NTR labeling	51812
the lateral edges of the spinal cord close to or in the dorsal root itself	51860
the lateral edges	51860
the spinal cord close to or in the dorsal root itself	51881
the spinal cord close	51881
the dorsal root	51912
the presence of Schwann cells	51947
the presence	51947
Schwann cells	51963
Histological analysis Double staining for fibronectin and p75NTR	51978
Histological analysis Double staining	51978
fibronectin and p75NTR	52020
scar-associated cells , such as meningeal cells and fibroblasts ,	52065
scar-associated cells	52065
meningeal cells and fibroblasts	52096
OEG	52143
4 months after the injury	52165
4 months	52165
the injury	52180
abundant fibronectin expression	52192
unimplanted animals	52237
the scar	52269
only a minor immunoreactivity for p75NTR	52283
only a minor immunoreactivity	52283
p75NTR	52317
Fig. 3A	52343
The majority of these p75NTR-labeled cells	52353
The majority	52353
these p75NTR-labeled cells	52369
the more lateral part of the lesion	52409
the more lateral part	52409
the lesion	52434
the dorsal root entry zone	52455
Most of these cells	52483
Most	52483
these cells	52491
typical bipolar morphology -LRB- Fig. 3A , inset -RRB- , indicating that they were most likely Schwann cells that had migrated into the spinal cord after the injury	52513
typical bipolar morphology -LRB- Fig. 3A , inset -RRB-	52513
typical bipolar morphology	52513
Fig. 3A , inset	52541
Fig. 3A	52541
they	52574
most likely Schwann cells that had migrated into the spinal cord after the injury	52584
most likely Schwann cells	52584
the spinal cord	52633
the injury	52655
contrast	52670
high levels of p75NTR immunoreactivity	52680
high levels	52680
p75NTR immunoreactivity	52695
all implanted animal groups , labeling many cells at the injury site but not rostral or caudal to it -LRB- Fig. 3B -RRB-	52736
all	52736
animal groups	52750
many cells	52774
the injury site but not rostral or caudal	52788
the injury site	52788
rostral or caudal	52812
it -LRB- Fig. 3B -RRB-	52833
it	52833
Fig. 3B	52837
This	52847
implanted OEG	52867
the spinal cord for at least 4 months	52905
the spinal cord	52905
at least 4 months	52925
implantation	52949
only a few p75NTR-positive Schwann cells	52971
the spinal cord	53033
Clusters of aligned p75NTR-positive cells , presumably	53050
Clusters	53050
p75NTR-positive cells	53070
OEG , together with some endogenous Schwann cells were surrounded by small fibronectin-positive cells , most likely derived from the meningeal sheets -LRB- Pasterkamp et al. , 1999 -RRB-	53114
OEG	53114
some endogenous Schwann cells were surrounded by small fibronectin-positive cells	53133
some endogenous Schwann	53133
cells	53157
small fibronectin-positive cells	53182
the meningeal sheets -LRB- Pasterkamp et al. , 1999 -RRB-	53241
the meningeal sheets	53241
Pasterkamp	53263
et al. , 1999	53274
et al.	53274
1999	53282
axonal staining	53308
few NFpositive axon-like structures	53325
the lesion area of unimplanted controls -LRB- Fig. 3C -RRB-	53375
the lesion area	53375
unimplanted controls -LRB- Fig. 3C -RRB-	53394
unimplanted controls	53394
Fig. 3C	53416
a dense network of NFpositive axons	53434
a dense network	53434
NFpositive axons	53453
OEG-implanted rats	53486
close association with p75NTR-positive cells -LRB- Fig. 3D -RRB-	53515
close association	53515
p75NTR-positive cells -LRB- Fig. 3D -RRB-	53538
p75NTR-positive cells	53538
Fig. 3D	53561
Anterograde tracing	53571
Anterograde	53571
implantation of OEG	53605
implantation	53605
OEG	53621
robust long-distance regeneration of RST fibers	53643
robust long-distance regeneration	53643
RST fibers	53680
any condition	53697
unimplanted animals	53715
the vast majority of traced RST axons -LRB- black -RRB-	53736
the vast majority	53736
traced RST axons -LRB- black -RRB-	53757
traced RST axons	53757
`` end bulb '' - like structures at the proximal border of the lesion site , in the GFAP-positive -LRB- brown -RRB- area	53792
`` end bulb ''	53792
structures at the proximal border of the lesion site	53808
structures	53808
the proximal border of the lesion site	53822
the proximal border	53822
the lesion site	53845
the GFAP-positive -LRB- brown -RRB- area	53865
brown	53884
the central component of the scar tissue -LRB- Fig. 4A , C -RRB-	53924
the central component	53924
the scar tissue -LRB- Fig. 4A , C -RRB-	53949
the scar tissue	53949
Fig. 4A , C	53966
Fig. 4A	53966
C	53974
animals that received an implant of uninfected , AdV-LacZ - or AdV-NT-3-transduced OEG , respectively	53981
animals	53981
an	54003
uninfected , AdV-LacZ - or AdV-NT-3-transduced OEG , respectively	54017
uninfected , AdV-LacZ - or AdV-NT-3-transduced OEG	54017
no obvious difference in the distribution of RST axons	54081
no obvious difference	54081
the distribution of RST axons	54106
the distribution	54106
RST axons	54126
nonimplanted animals -LRB- Fig. 4B , D , E -RRB-	54163
nonimplanted animals	54163
Fig. 4B	54185
D	54193
E	54195
extensive BDNF-mediated sprouting of RST axons	54208
extensive BDNF-mediated	54208
RST axons	54245
animals that received an OEG implant that was transduced with AdV-BDNF alone or together with AdVNT - 3	54271
animals	54271
an OEG	54293
that	54308
AdV-BDNF	54333
AdVNT	54365
3	54372
Sprouting of RST axons	54375
Sprouting	54375
RST axons	54388
the interface of the injury site and astrocytic scar -LRB- Fig. 4F -RRB-	54428
the interface	54428
the injury site and astrocytic scar -LRB- Fig. 4F -RRB-	54445
the injury site and astrocytic scar	54445
Fig. 4F	54482
many cases	54495
aberrant and undirectional sprouting of RST axons	54507
aberrant and undirectional sprouting	54507
RST axons	54547
Fig. 4G	54571
I	54579
Sprouting of RST axons	54583
Sprouting	54583
RST axons	54596
the lesion area	54634
a small number of fibers extending beyond the lesion and implantation site in the distal spinal cord	54656
a small number	54656
fibers extending beyond the lesion and implantation site in the distal spinal cord	54674
fibers	54674
the lesion and implantation site in the distal spinal cord	54698
the lesion and implantation site	54698
the distal spinal cord	54734
most of these axons	54767
most	54767
these axons	54775
close proximity of the injury site -LRB- Fig. 4H , J -RRB-	54801
close proximity	54801
the injury site -LRB- Fig. 4H , J -RRB-	54820
the injury site	54820
Fig. 4H , J	54837
Fig. 4H	54837
J	54845
each experimental group	54854
camera lucida drawings through the lesion area of a representative animal	54879
camera lucida drawings	54879
the lesion area of a representative animal	54910
the lesion area	54910
a representative animal	54929
the spatial relationship of traced RST axons	54981
the spatial relationship	54981
traced RST axons	55009
the lesion area -LRB- Fig. 5 -RRB-	55029
the lesion area	55029
Fig. 5	55046
Microscopic observations	55055
quantitative analysis of the regenerative response of rubrospinal neurons	55098
quantitative analysis	55098
the regenerative response of rubrospinal neurons	55123
the regenerative response	55123
rubrospinal neurons	55152
different OEG implants -LRB- Fig. 6 -RRB-	55175
different OEG implants	55175
Fig. 6	55199
Fiber counts of BDA-traced RST axons	55208
Fiber counts	55208
BDA-traced RST axons	55224
no statistical differences	55259
animal groups that received either no treatment -LRB- n = 6 -RRB- with an implant of uninfected OEG -LRB- p = 0.52 ; n = 9 -RRB- or AdVLacZ - transduced OEG -LRB- p = 0.12 ; n = 6 -RRB-	55307
animal groups	55307
no treatment -LRB- n = 6 -RRB- with an implant of uninfected OEG -LRB- p = 0.52 ; n = 9 -RRB- or AdVLacZ - transduced OEG	55342
no treatment -LRB- n = 6 -RRB-	55342
no treatment	55342
n	55356
6	55358
an implant of uninfected OEG -LRB- p = 0.52 ; n = 9 -RRB- or AdVLacZ - transduced OEG	55366
uninfected OEG -LRB- p = 0.52 ; n = 9 -RRB- or AdVLacZ -	55380
uninfected OEG	55380
p = 0.52 ; n = 9	55397
p	55397
= 0.52 ; n = 9	55399
= 0.52	55399
n = 9	55407
n	55407
9	55411
AdVLacZ	55417
p = 0.12 ; n = 6	55443
p	55443
= 0.12 ; n = 6	55445
= 0.12	55445
=	55445
0.12	55447
n = 6	55453
n	55453
6	55457
AdV vector-mediated hypersecretion of NT-3 from transduced OEG	55475
AdV vector-mediated hypersecretion	55475
NT-3 from transduced OEG	55513
NT-3	55513
OEG	55534
growth of RST axons	55560
growth	55560
RST axons	55570
`` dieback '' -LRB- p ≥ 0.28 ; n = 7 -RRB-	55601
`` dieback ''	55601
p ≥	55613
0.28 ; n = 7	55615
0.28	55615
n = 7	55621
n	55621
7	55624
all cases	55631
a similar distribution pattern and dieback of RST axons	55642
a similar distribution pattern and dieback	55642
RST axons	55688
a consistent tendency toward limited local sprouting	55722
a consistent tendency	55722
limited local sprouting	55751
limited local	55751
these OEG	55793
groups	55813
These data	55821
RST axons	55846
OEG implants	55885
an additional AdV vector-mediated expression of NT-3 by implanted cells	55903
an additional AdV vector-mediated expression	55903
NT-3 by implanted cells	55951
NT-3	55951
implanted cells	55959
a regenerative response of RST axons	55989
a regenerative response	55989
RST axons	56016
the histological observations	56044
a statistically significant BDNF-mediated sprouting of RST axons	56075
a statistically significant BDNF-mediated	56075
RST axons	56130
animal groups	56153
4 -LRB- p ≤ 0.0002 ; n = 5 -RRB- and 6 -LRB- p ≤ 0.004 ; n = 7 -RRB-	56167
4	56167
p ≤	56171
0.0002 ; n = 5	56175
0.0002	56175
n = 5	56183
n	56183
5	56187
6	56194
p ≤ 0.004 ; n = 7	56198
p	56198
≤ 0.004 ; n = 7	56200
≤ 0.004	56200
n = 7	56209
n	56209
7	56213
all other animal groups	56230
No statistical differences	56255
these two groups -LRB- p = 0.33 -RRB-	56301
these two groups	56301
p	56320
0.33	56324
coexpression of BDNF and NT-3	56347
coexpression	56347
BDNF and NT-3	56363
no synergistic	56381
effect	56413
the level of RST axon sprouting	56423
the level	56423
RST axon	56436
Volumetric analysis of the injury site	56456
Volumetric analysis	56456
the injury site	56479
a consistent trend toward smaller lesion volumes	56509
a consistent trend	56509
smaller lesion volumes	56535
all OEG implanted rats compared with controls -LRB- Fig. 7 -RRB-	56573
all OEG	56573
rats	56591
controls -LRB- Fig. 7 -RRB-	56610
controls	56610
Fig. 7	56620
no statistically significant differences from unimplanted controls -LRB- n = 6 -RRB-	56638
no statistically significant differences	56638
unimplanted controls -LRB- n = 6 -RRB-	56684
unimplanted controls	56684
n	56706
6	56708
animals implanted with uninfected OEG -LRB- p ≤ 0.08 ; n = 9 -RRB- or AdV-LacZ-transduced OEG -LRB- p = 0.11 ; n = 6 -RRB- , respectively	56727
animals	56727
uninfected OEG -LRB- p ≤ 0.08 ; n = 9 -RRB- or AdV-LacZ-transduced OEG -LRB- p = 0.11 ; n = 6 -RRB-	56750
uninfected OEG	56750
p ≤ 0.08 ; n = 9	56767
p	56767
≤ 0.08 ; n = 9	56769
≤ 0.08	56769
n = 9	56777
n	56777
9	56781
AdV-LacZ-transduced OEG	56787
p	56813
= 0.11 ; n = 6	56815
= 0.11	56815
n = 6	56823
n	56823
6	56827
contrast	56848
lesion volumes	56858
half	56896
animals that received OEG implants transduced with AdV vectors encoding BDNF -LRB- p = 0.008 ; n = 5 -RRB- , NT-3 -LRB- p = 0.01 ; n = 9 -RRB- , or a mixture of both vectors -LRB- p = 0.004 ; n = 7 -RRB-	56904
animals	56904
OEG implants transduced with AdV vectors encoding BDNF -LRB- p = 0.008 ; n = 5 -RRB- , NT-3 -LRB- p = 0.01 ; n = 9 -RRB- , or a mixture of both vectors -LRB- p = 0.004 ; n = 7 -RRB-	56926
OEG implants transduced with AdV vectors encoding BDNF -LRB- p = 0.008 ; n = 5 -RRB- , NT-3 -LRB- p = 0.01 ; n = 9 -RRB- , or a mixture of both vectors	56926
OEG implants transduced with AdV vectors	56926
OEG implants	56926
AdV vectors	56955
encoding BDNF -LRB- p = 0.008 ; n = 5 -RRB- , NT-3 -LRB- p = 0.01 ; n = 9 -RRB- , or a mixture of both vectors	56967
encoding BDNF -LRB- p = 0.008 ; n = 5 -RRB-	56967
encoding BDNF	56967
p = 0.008 ; n = 5	56983
p	56983
= 0.008 ; n = 5	56984
= 0.008	56984
n = 5	56992
n	56992
5	56994
NT-3 -LRB- p = 0.01 ; n = 9 -RRB-	56998
NT-3	56998
p = 0.01 ; n = 9	57005
p = 0.01	57005
p	57005
0.01	57007
n = 9	57013
n	57013
9	57016
a mixture of both vectors	57023
a mixture	57023
both vectors	57036
p = 0.004 ; n = 7	57051
p	57051
= 0.004 ; n = 7	57052
= 0.004	57052
n = 7	57060
n	57060
7	57062
This	57066
AdV vector-mediated secretion of BDNF and NT-3	57086
AdV vector-mediated secretion	57086
BDNF and NT-3	57119
secondary degeneration of neural tissue	57146
secondary degeneration	57146
neural tissue	57172
experimental spinal cord injury	57192
MEP analysis	57225
unoperated age-matched controls	57241
unilateral stimulation of the red nucleus	57274
unilateral stimulation	57274
the red nucleus	57300
the recording of a few detectable peaks	57328
the recording	57328
a few detectable peaks	57345
the level of cervical vertebra C6 -LRB- Fig. 8 -RRB-	57371
the level	57371
cervical vertebra C6 -LRB- Fig. 8 -RRB-	57384
cervical vertebra C6	57384
Fig. 8	57406
The first peak	57415
the direct projection	57441
the red nucleus	57468
its amplitude -LRB- a direct measure for the number of RST axons -RRB-	57489
its amplitude	57489
a direct measure for the number of RST axons	57504
a direct measure	57504
the number of RST axons	57525
the number	57525
RST axons	57539
signifi - cantly decreased after transection of the dorsolateral funiculus -LRB- p < 0.001 -RRB-	57553
signifi	57553
transection of the dorsolateral funiculus -LRB- p < 0.001 -RRB-	57585
transection	57585
the dorsolateral funiculus -LRB- p < 0.001 -RRB-	57600
the dorsolateral funiculus	57600
p < 0.001	57629
p	57629
< 0.001	57632
<	57632
0.001	57634
The other detectable peaks	57642
unidentified descending spinal pathways that are either costimulated during MEP recording or part of the larger motor system that involves the red nucleus	57689
unidentified descending spinal pathways	57689
MEP recording or part of the larger motor system that involves the red nucleus	57765
MEP recording or part	57765
the larger motor system that involves the red nucleus	57790
the larger motor system	57790
the red nucleus	57828
line with our histological observations	57848
line	57848
our histological observations	57858
no significant differences in rubrospinal MEP recordings	57889
no significant differences	57889
rubrospinal MEP recordings	57919
different experimental animal groups -LRB- p > 0.05 ; data not shown -RRB- , indicating the absence of robust long-distance regeneration of axons beyond OEG implants -LRB- Fig. 8 -RRB-	57963
different experimental animal groups -LRB- p > 0.05 ; data not shown -RRB- ,	57963
different experimental animal groups	57963
p > 0.05 ; data not shown -RRB-	58002
p	58002
0.05	58006
data	58012
the absence of robust long-distance regeneration of axons	58040
the absence	58040
robust long-distance regeneration of axons	58055
robust long-distance regeneration	58055
axons	58092
OEG implants -LRB- Fig. 8 -RRB-	58105
OEG implants	58105
Fig. 8	58119
Analysis of functional recovery Behavioral analysis of spinal cord-injured rats during overground locomotion -LRB- BBB score -RRB-	58128
Analysis of functional recovery Behavioral analysis of spinal cord-injured rats during overground locomotion	58128
Analysis	58128
functional recovery Behavioral analysis of spinal cord-injured rats during overground locomotion	58140
functional recovery Behavioral analysis	58140
spinal cord-injured rats during overground locomotion	58183
spinal cord-injured rats	58183
overground locomotion	58215
BBB score	58238
detectable functional deficits in the open field	58264
detectable functional deficits	58264
the open field	58298
a transient impairment	58323
the initial postoperative phase in both the left forelimb and hindlimb	58366
the initial postoperative phase	58366
both the left forelimb and hindlimb	58401
the left forelimb	58406
hindlimb	58428
animals	58438
the injury	58473
treatment -LRB- data not shown -RRB-	58498
treatment	58498
data not shown	58509
data	58509
This	58526
the BBB rating score	58549
an inappropriate assay for evaluation of hindlimb function recovery after partial transection of the dorsolateral funiculus , as stated previously -LRB- Kim et al. , 2001 -RRB-	58573
an inappropriate assay	58573
evaluation of hindlimb function recovery after partial transection of the dorsolateral funiculus , as stated previously -LRB- Kim et al. , 2001 -RRB-	58600
evaluation	58600
hindlimb function recovery after partial transection of the dorsolateral funiculus , as stated previously -LRB- Kim et al. , 2001 -RRB-	58614
hindlimb function recovery	58614
partial transection of the dorsolateral funiculus , as stated previously -LRB- Kim et al. , 2001 -RRB-	58647
partial transection	58647
the dorsolateral funiculus , as stated previously	58670
the dorsolateral funiculus	58670
Kim	58720
et al. , 2001	58724
et al.	58724
2001	58732
contrast	58742
a persistent impairment in especially ipsilateral hindlimb function	58752
a persistent impairment	58752
especially ipsilateral hindlimb function	58779
horizontal rope walking	58840
the hindlimb or even a fall	58887
the hindlimb	58887
even a fall	58903
the rope -LRB- Fig. 9A -RRB-	58920
the rope	58920
Fig. 9A	58930
Such impairment	58940
pretraining of the animals	58979
pretraining	58979
the animals	58994
spinal injury	59013
all operated animals	59031
all	59031
animals	59044
remaining deficits in general locomotion and hindlimb performance	59053
remaining deficits	59053
general locomotion and hindlimb performance	59075
a statistically significant main treatment effect in deficit	59143
a statistically significant main treatment effect	59143
deficit	59196
scores was found -LRB- p ≤ 0.0002 -RRB-	59204
scores	59204
p	59223
≤ 0.0002	59225
Fig. 9B	59236
This	59246
allOEGimplanted rats	59266
a consistently improved locomotion	59291
the rope	59351
unimplanted control animals	59381
no differences in locomotor behavior	59423
no differences	59423
locomotor behavior	59441
animals that received an implant of uninfected or AdVLacZ - transduced OEG , respectively -LRB- p = 0.99 -RRB-	59479
animals	59479
an implant of uninfected or AdVLacZ - transduced OEG , respectively	59501
uninfected or AdVLacZ	59515
uninfected	59515
AdVLacZ	59529
OEG	59549
p	59569
0.99	59573
This	59580
ex vivo transduction of OEG itself	59603
ex vivo transduction	59603
OEG itself	59627
OEG	59627
AdV vector-mediated gene transfer	59645
AdV	59645
vector-mediated gene transfer	59649
the behavioral outcome	59703
addition	59730
rope locomotion behavior	59740
animals	59792
an OEG	59814
that	59829
a neurotrophin-encoding AdV vector	59854
p	59891
≤ 0.00002	59893
the fact that these rats made fewer errors during rope traverse	59916
the fact	59916
these rats	59930
fewer errors	59946
rope traverse	59966
other locomotion aspects , in particular body posture and hindpaw placement ,	59981
other locomotion aspects	59981
particular body posture and hindpaw placement	60010
these groups com	60074
animals from control groups -LRB- lesion only or control OEG implant -RRB- -LRB- Fig. 9A -RRB-	60103
animals	60103
control groups -LRB- lesion only or control OEG implant -RRB- -LRB- Fig. 9A -RRB-	60116
control groups -LRB- lesion only or control OEG implant -RRB-	60116
control groups	60116
lesion only or control OEG implant	60132
lesion only	60132
OEG	60155
Fig. 9A	60169
These observations	60179
the significantly lower deficit scores	60216
all experimental groups	60278
no significant additional improvements in functional performance	60303
no significant additional improvements	60303
functional performance	60345
the first month	60385
surgery	60407
This	60416
recovery of function	60436
recovery	60436
function	60448
the first 4 weeks	60483
injury and OEG implantation	60507
total error/step ratios	60547
the behavioral data	60592
the deficit-scoring method -LRB- Fig. 9C -RRB-	60629
the deficit-scoring method	60629
Fig. 9C	60657
Significant treatment-based differences	60667
the experimental groups	60724
All OEG-implanted animal groups	60749
an improved recovery	60791
the injury resulting in significantly lower error scores -LRB- fewer slips or falls -RRB-	60818
the injury	60818
significantly lower error scores	60842
fewer slips or falls	60876
fewer	60876
unimplanted lesioned control rats -LRB- p ≤ 0.0003 -RRB-	60903
unimplanted lesioned control rats	60903
p ≤ 0.0003	60939
p	60939
≤ 0.0003	60940
no statistical difference -LRB- p = 0.57 -RRB- in horizontal rope locomotion performance	60957
no statistical difference -LRB- p = 0.57 -RRB-	60957
no statistical difference	60957
p	60985
0.57	60989
horizontal rope locomotion performance	60998
rats that received an implant of either uninfected or AdVLacZ - transduced OEG	61053
rats	61053
an implant of either uninfected or AdVLacZ - transduced OEG	61072
either uninfected or AdVLacZ	61086
uninfected	61093
AdVLacZ	61107
OEG	61127
recovery	61141
animal groups that received OEG implants subjected to transduction with neurotrophin-encoding AdV vector	61166
animal groups	61166
OEG implants subjected to transduction with neurotrophin-encoding AdV vector	61194
OEG implants	61194
transduction	61220
neurotrophin-encoding AdV vector	61238
AdVLacZ - transducedOEGimplanted rats	61291
AdVLacZ	61291
transducedOEGimplanted rats	61300
fewer errors	61329
animals implanted with AdV-BDNF-transduced OEG	61359
animals	61359
AdV-BDNF-transduced OEG	61382
this	61411
statistical significance -LRB- p = 0.07 -RRB-	61435
statistical significance	61435
p	61462
0.07	61466
statistically significant improvements	61482
implantation of AdV-NT-3OEG -LRB- p = 0.02 -RRB- or AdVBDNF / NT-3-transduced OEG	61541
implantation	61541
AdV-NT-3OEG -LRB- p = 0.02 -RRB- or AdVBDNF / NT-3-transduced OEG	61557
AdV-NT-3OEG	61557
p	61570
0.02	61572
AdVBDNF	61581
NT-3-transduced OEG	61590
p = 0.009	61612
p	61612
= 0.009	61613
these data	61632
neurotrophin-encoding AdV	61660
OEG implants	61703
the best recovery	61723
injury	61747
all OEGimplanted animal groups	61763
unimplanted lesioned controls	61832
a significant positive correlation	61878
the error scores of the impaired -LRB- left -RRB- hindpaw of individual animals and accompanying lesion volumes -LRB- Pearson 's correlation test ; r 0.632 ; p 0.001 -RRB-	61929
the error scores	61929
the impaired -LRB- left -RRB- hindpaw of individual animals and accompanying lesion volumes -LRB- Pearson 's correlation test ; r 0.632 ; p 0.001 -RRB-	61949
the impaired -LRB- left -RRB- hindpaw	61949
individual animals and accompanying lesion volumes	61980
individual animals	61980
accompanying lesion volumes	62003
Pearson 's correlation test ; r 0.632 ; p 0.001	62032
Pearson 's correlation test ; r 0.632 ; p	62032
Pearson 's correlation test	62032
Pearson 's	62032
r 0.632 ; p	62060
r 0.632	62060
p	62071
0.001	62073
Rats that performed well during horizontal rope walking -LRB- low error score -RRB-	62081
Rats that performed well during horizontal rope walking	62081
Rats	62081
horizontal rope walking	62113
low error score	62138
relatively small lesions	62174
animals that slipped or fell from the rope more frequently	62208
animals	62208
the rope	62242
bigger lesion volumes -LRB- Fig. 9D -RRB-	62284
bigger lesion volumes	62284
Fig. 9D	62307
This	62317
possible neuroprotective effects of BDNF and NT-3 , counteracting secondary degeneration ,	62336
possible neuroprotective effects	62336
BDNF and NT-3	62372
secondary degeneration	62401
the functional performance of animals	62447
the functional performance	62447
animals	62477
horizontal rope locomotion , which would also be in line with the time course of recovery	62492
horizontal rope locomotion	62492
line	62543
the time course of recovery	62553
the time course	62553
recovery	62572
Discussion The present study uniquely	62583
Discussion	62583
The present study	62594
OEG implantation	62630
ex vivo AdV vector-mediated neurotrophin gene transfer	62652
ex vivo AdV	62652
vector-mediated neurotrophin gene transfer	62664
We	62708
the following : -LRB- 1 -RRB- OEG implants transduced with neurotrophinencoding AdV vectors augmented enhanced recovery of hindlimb function compared with controls	62723
the following	62723
-LRB- 1 -RRB- OEG implants transduced with neurotrophinencoding AdV vectors augmented enhanced recovery of hindlimb function compared with controls	62738
OEG	62742
implants transduced with neurotrophinencoding AdV vectors augmented enhanced recovery	62746
implants	62746
neurotrophinencoding AdV vectors augmented enhanced recovery	62771
neurotrophinencoding AdV vectors	62771
enhanced recovery	62814
hindlimb function	62835
controls	62867
behavioral testing	62893
Lesion volumes	62917
OEG-implanted animals	62948
size	62999
rats receiving a graft that was ex vivo transduced with neurotrophin-encoding AdV vector	63007
rats	63007
a graft that was ex vivo transduced with neurotrophin-encoding AdV vector	63022
a graft	63022
ex vivo transduced with neurotrophin-encoding AdV vector	63039
ex vivo	63039
neurotrophin-encoding AdV vector	63063
A positive correlation	63101
functional impairment and lesion size	63142
reduction of secondary damage by OEG implants	63197
reduction	63197
secondary damage by OEG implants	63210
secondary damage	63210
OEG implants	63230
an improved functional outcome	63252
Extensive BDNF-stimulated sprouting of RST axons	63288
Extensive BDNF-stimulated	63288
RST axons	63327
1 -- 1.5 mm	63355
1	63355
1.5 mm	63357
the lesion area	63369
there	63390
no obvious correlation with behavioral data	63400
no obvious correlation	63400
behavioral data	63428
Quantitative histological and electrophysiological analysis	63445
OEG	63517
major long-distance RST regeneration	63536
the correlation between lesion size and functional performance	63585
the correlation	63585
lesion size and functional performance	63609
lesion size	63609
functional performance	63625
the recovery	63663
protective effects of OEG implants	63710
protective effects	63710
OEG implants	63732
the surrounding spinal cord	63748
Functional performance	63777
lesion size All OEG-implanted animals displayed better functional performance during horizontal rope walking , which was also enhanced in rats receiving an implant of neurotrophin-encoding AdV vector-transduced OEG	63816
lesion size	63816
All OEG-implanted animals	63828
better functional performance	63864
horizontal rope walking , which was also enhanced in rats receiving an implant of neurotrophin-encoding AdV vector-transduced OEG	63901
horizontal rope walking	63901
rats receiving an implant of neurotrophin-encoding AdV vector-transduced OEG	63953
rats	63953
an	63968
neurotrophin-encoding AdV vector-transduced OEG	63982
Functional studies on the physiological role of the red nucleus	64031
Functional studies	64031
the physiological role of the red nucleus	64053
the physiological role	64053
the red nucleus	64079
its specific ablation	64118
persistent , although minor , deficits	64151
hindlimb functioning -LRB- Muir and Whishaw , 2000	64191
hindlimb functioning -LRB- Muir and Whishaw	64191
hindlimb functioning	64191
Muir and Whishaw	64213
Muir	64213
Whishaw	64222
2000	64231
This	64238
the observed impairments in hindlimb performance during horizontal rope walking	64257
the observed impairments	64257
hindlimb performance during horizontal rope walking	64285
hindlimb performance	64285
horizontal rope walking	64313
a loss of rubral input	64367
a loss	64367
rubral input	64377
Damage to other motor pathways in the lateral funiculus -LRB- Holstege , 1991 -RRB- likely	64391
Damage	64391
other motor pathways in the lateral funiculus -LRB- Holstege , 1991 -RRB- likely	64401
other motor pathways	64401
the lateral funiculus -LRB- Holstege , 1991 -RRB- likely	64425
the lateral funiculus -LRB- Holstege , 1991 -RRB-	64425
the lateral funiculus	64425
Holstege	64448
1991	64458
these remaining deficits	64486
The striking correlation between lesion size and functional performance	64512
The striking correlation	64512
lesion size and functional performance	64545
lesion size	64545
functional performance	64561
the degree of recovery	64599
the degree	64599
recovery	64613
the protective potential of OEG implants , which is a novel finding	64644
the protective potential	64644
OEG implants , which is a novel finding	64672
OEG implants	64672
a novel finding	64695
OEGmediated tissue sparing	64722
a contusion injury model -LRB- Takami et al. , 2002 ; Plant et al. , 2003 -RRB-	64771
a contusion injury model	64771
Takami	64797
et al. , 2002 ; Plant et al. , 2003	64804
et al.	64804
2002 ; Plant et al.	64812
2002	64812
Plant et al.	64818
Plant	64818
et al.	64824
2003	64832
it	64848
this also improved functional recovery	64885
A significant reduction in lesion size	64925
A significant reduction	64925
lesion size	64952
implantation of OEG transduced with neurotrophin-encoding AdV vectors	64985
implantation	64985
OEG transduced with neurotrophin-encoding AdV vectors	65001
OEG	65001
neurotrophin-encoding AdV vectors	65021
This	65056
BDNF and NT-3	65076
secondary tissue degeneration	65103
Such a restorative role for neurotrophins	65134
Such a restorative role	65134
neurotrophins	65162
BDNF	65201
tissue necrosis	65231
spinal cord injury -LRB- Novikova et al. , 1996 -RRB-	65253
spinal cord injury	65253
Novikova	65273
et al. , 1996	65282
et al.	65282
1996	65290
This feature	65297
spinal tissue sparing , in particular ventrolateral white matter ,	65331
spinal tissue sparing	65331
particular ventrolateral white matter	65357
the locomotor capacity of spinal cord-injured rats -LRB- Schucht et al. , 2002 -RRB-	65425
the locomotor capacity	65425
spinal cord-injured rats -LRB- Schucht et al. , 2002 -RRB-	65451
spinal cord-injured rats	65451
Schucht	65477
et al. , 2002	65485
et al.	65485
2002	65493
both BDNF and NT-3	65513
oligodendrocyte proliferation and remyelination of damaged axons -LRB- McTigue et al. , 1998 -RRB- , which is of interest because remaining deficits after injury are partly caused by demyelination of spared axons	65558
oligodendrocyte proliferation and remyelination	65558
damaged axons -LRB- McTigue et al. , 1998 -RRB- , which is of interest because remaining deficits after injury are partly caused by demyelination of spared axons	65609
damaged axons -LRB- McTigue et al. , 1998 -RRB-	65609
damaged axons	65609
McTigue	65624
et al. , 1998	65632
et al.	65632
1998	65640
interest	65659
remaining deficits after injury	65676
remaining deficits	65676
injury	65701
demyelination of spared axons	65729
demyelination	65729
spared axons	65746
we	65770
lesion size	65790
impaired hindlimb performance	65833
This	65864
the idea that neurotrophin-mediated tissue preservation after implantation of AdV vector-transduced OEG in the subacute phase after injury contributed to the level of functional recovery rather than regeneration of the RST itself	65878
the idea that neurotrophin-mediated tissue preservation after implantation of AdV vector-transduced OEG in the subacute phase after injury contributed to the level of functional recovery	65878
the idea	65878
neurotrophin-mediated tissue preservation after implantation of AdV vector-transduced OEG in the subacute phase after injury	65892
neurotrophin-mediated tissue preservation	65892
implantation of AdV vector-transduced OEG in the subacute phase after injury	65940
implantation	65940
AdV vector-transduced OEG in the subacute phase after injury	65956
AdV vector-transduced OEG	65956
the subacute phase after injury	65985
the subacute phase	65985
injury	66010
the level of functional recovery	66032
the level	66032
functional recovery	66045
regeneration of the RST itself	66077
regeneration	66077
the RST itself	66093
the RST	66093
AdV vector-transduced OEG implants and RST regeneration Genetic modification	66109
AdV vector-transduced OEG implants	66109
AdV	66109
vector-transduced OEG implants	66113
RST regeneration Genetic modification	66148
RST regeneration	66148
Genetic modification	66165
us	66194
the growthpromoting properties of OEG	66211
the growthpromoting properties	66211
OEG	66245
In vitro , transduction ofOEGwith AdV-BDNF or AdV-NT-3	66250
In vitro	66250
transduction ofOEGwith AdV-BDNF	66260
AdV-NT-3	66295
a cell type that was more effective in promoting neurite growth	66316
a cell type	66316
neurite growth	66365
In vivo , only AdV-BDNFtransduced OEG	66381
In vivo	66381
only AdV-BDNFtransduced OEG	66390
a significant regenerative response of RST axons	66443
a significant regenerative response	66443
RST axons	66482
previous work , using ex vivo lentiviral vector-transduced OEG expressing the marker protein green fluorescent protein to reliably track implanted cells	66496
previous work	66496
ex vivo	66517
lentiviral vector-transduced OEG expressing the marker protein green fluorescent protein to reliably track implanted cells	66525
lentiviral vector-transduced OEG	66525
the marker protein green fluorescent protein to reliably track implanted cells	66569
the marker protein	66569
green fluorescent protein	66588
implanted cells	66632
we	66649
implanted OEG	66684
the lesioned spinal cord at least	66713
the lesioned spinal cord	66713
up to 4 months -LRB- Ruitenberg et al. , 2002 -RRB-	66747
up to 4 months	66747
Ruitenberg	66763
et al. , 2002	66774
et al.	66774
2002	66782
This	66789
these conditions	66815
the absence of elevated BDNF levels	66839
the absence	66839
elevated BDNF levels	66854
lesioned RST axons	66876
OEG implants	66922
date	66939
a number of axon populations	66945
a number	66945
axon populations	66957
OEG implants in different injury models	67010
OEG implants	67010
different injury models	67026
sensory axons of the dorsal root axons -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Navarro et al. , 1999 -RRB- as well as serotonergic axons -LRB- Ramon-Cueto et al. , 1998 , 2000 ; Lu et al. , 2001a , 2002 -RRB- and CST axons -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	67061
sensory axons	67061
the dorsal root axons -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Navarro et al. , 1999 -RRB- as well as serotonergic axons -LRB- Ramon-Cueto et al. , 1998 , 2000 ; Lu et al. , 2001a , 2002 -RRB- and CST axons -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	67078
the dorsal root axons -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Navarro et al. , 1999 -RRB-	67078
the dorsal	67078
root axons -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Navarro et al. , 1999 -RRB-	67089
root axons	67089
Ramon-Cueto and Nieto-Sampedro , 1994 ; Navarro et al. , 1999	67101
Ramon-Cueto and Nieto-Sampedro	67101
1994 ; Navarro et al.	67133
1994	67133
Navarro et al.	67139
Navarro	67139
et al.	67147
1999	67155
serotonergic axons -LRB- Ramon-Cueto et al. , 1998 , 2000 ; Lu et al. , 2001a , 2002 -RRB- and CST axons -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	67172
serotonergic axons -LRB- Ramon-Cueto et al. , 1998 , 2000 ; Lu et al. , 2001a , 2002 -RRB-	67172
serotonergic axons	67172
Ramon-Cueto et al. , 1998 , 2000 ; Lu et al. , 2001a , 2002	67192
Ramon-Cueto et al.	67192
Ramon-Cueto	67192
et al.	67204
1998 , 2000 ; Lu et al.	67212
1998 , 2000	67212
1998	67212
2000	67218
Lu et al.	67224
Lu	67224
et al.	67227
2001a , 2002	67235
2001a	67235
2002	67242
CST axons -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 -RRB-	67252
CST axons	67252
Li	67263
et al. , 1998 ; Ramon-Cueto et al. , 2000	67266
et al.	67266
1998 ; Ramon-Cueto et al.	67274
1998	67274
Ramon-Cueto et al.	67280
Ramon-Cueto	67280
et al.	67292
2000	67300
Some controversy	67307
the regenerative response of the CST	67338
the regenerative response	67338
the CST	67367
others	67383
OEGinduced sprouting	67401
OEGinduced	67401
the proximal injury site	67437
the RST -LRB- Takami et al. , 2002 ; D. B. Levison , M. J. Ruitenberg , G. W. Plant , unpublished observations -RRB-	67483
the RST	67483
Takami et al. , 2002 ; D. B. Levison , M. J. Ruitenberg , G. W. Plant , unpublished observations	67492
Takami et al.	67492
Takami	67492
et al.	67499
2002 ; D. B. Levison	67507
2002	67507
D. B. Levison	67513
M. J. Ruitenberg	67528
G. W. Plant , unpublished observations	67546
G. W. Plant	67546
unpublished observations	67559
It	67586
more insight in both OEG cell biology and specific neurotrophic requirements of the different spinal pathways	67622
more insight	67622
both OEG cell biology and specific neurotrophic requirements	67638
OEG cell biology	67643
specific neurotrophic requirements	67664
the different spinal pathways	67702
Extended knowledge of proteins involved in regeneration of specific nerve tracts	67733
Extended knowledge	67733
proteins involved in regeneration of specific nerve tracts	67755
proteins	67755
regeneration of specific nerve tracts	67776
regeneration	67776
specific nerve tracts	67792
the development of more optimal bridging substrates via genetic engineering	67825
the development	67825
more optimal bridging substrates via genetic engineering	67844
more optimal	67844
substrates via genetic engineering	67866
substrates	67866
genetic engineering	67881
Intraparenchymal infusions ofBDNFinduce	67902
regeneration of supraspinal axons	67951
regeneration	67951
supraspinal axons	67967
the RST -LRB- Xu et al. , 1995 ; Kobayashi et al. , 1997 -RRB-	67996
the RST	67996
Xu	68005
et al. , 1995 ; Kobayashi et al. , 1997	68008
et al.	68008
1995 ; Kobayashi et al.	68016
1995	68016
Kobayashi et al.	68022
Kobayashi	68022
et al.	68032
1997	68040
a gene therapy-based strategy to deliver neurotrophins	68056
a gene therapy-based strategy	68056
neurotrophins	68097
several advantages over the use of osmotic minipumps -LRB- for review , see Dijkhuizen and Verhaagen , 1999 -RRB-	68115
several advantages	68115
the use of osmotic minipumps -LRB- for review , see Dijkhuizen and Verhaagen , 1999 -RRB-	68139
the use	68139
osmotic minipumps	68150
review , see Dijkhuizen and Verhaagen , 1999	68173
review	68173
see Dijkhuizen and Verhaagen , 1999	68181
Dijkhuizen and Verhaagen , 1999	68185
Dijkhuizen and Verhaagen	68185
1999	68211
date	68221
engineered Schwann cells -LRB- Menei et al. , 1998 -RRB- and fibroblasts -LRB- Liu et al. , 1999 ; Lu et al. , 2001b -RRB-	68227
engineered Schwann cells -LRB- Menei et al. , 1998 -RRB- and fibroblasts	68227
engineered Schwann cells -LRB- Menei et al. , 1998 -RRB-	68227
engineered Schwann cells	68227
Menei	68253
et al. , 1998	68259
et al.	68259
1998	68267
fibroblasts	68277
Liu	68290
et al. , 1999 ; Lu et al. , 2001b	68294
et al.	68294
1999 ; Lu et al.	68302
1999	68302
Lu et al.	68308
Lu	68308
et al.	68311
2001b	68319
BDNF	68352
the injured spinal cord	68360
Vigorous growth of RST axons	68385
Vigorous growth	68385
RST axons	68404
implantation of BDNF-secreting fibroblasts -LRB- Liu et al. , 1999 -RRB-	68433
implantation	68433
BDNF-secreting fibroblasts -LRB- Liu et al. , 1999 -RRB-	68449
BDNF-secreting fibroblasts	68449
Liu	68477
et al. , 1999	68481
et al.	68481
1999	68489
the present study	68499
only short-range BDNF-mediated sprouting	68518
only short-range	68518
This discrepancy in experimental outcome between our study and the findings of Liu et al. -LRB- 1999 -RRB- is likely	68573
This discrepancy	68573
experimental outcome between our study and the findings of Liu	68593
experimental outcome between our study	68593
experimental outcome	68593
our study	68622
the findings of Liu	68636
the findings	68636
Liu	68652
et al. -LRB- 1999 -RRB-	68656
et al.	68656
1999	68664
several differences in treatment conditions -LRB- i.e. , the duration of transgene expression and num - ber of implanted cells -RRB-	68693
several differences	68693
treatment conditions	68716
i.e. , the duration of transgene expression and num - ber of implanted cells	68738
i.e.	68738
the duration of transgene expression and num - ber of implanted cells	68744
the duration of transgene expression and num	68744
the duration	68744
transgene expression and num	68760
ber of implanted cells	68790
ber	68790
implanted cells	68797
AdV vector-mediated transduction of OEG	68833
AdV vector-mediated transduction	68833
OEG	68869
a transient time course of transgene expression	68884
a transient time course	68884
transgene expression	68911
implantation in the lesioned spinal cord -LRB- up to 30 d -RRB- -LRB- Ruitenberg et al. , 2002 -RRB-	68938
implantation	68938
the lesioned spinal cord -LRB- up to 30 d -RRB- -LRB- Ruitenberg et al. , 2002 -RRB-	68954
the lesioned spinal cord -LRB- up to 30 d -RRB-	68954
the lesioned spinal cord	68954
30 d	68986
Ruitenberg	68993
et al. , 2002	69004
et al.	69004
2002	69012
persistent expression and thereby continuous neurotrophic support	69027
persistent expression	69027
continuous neurotrophic support	69061
engineered fibroblast grafts	69108
future studies	69141
it	69157
RST regeneration	69192
implantation of stable transduced OEG -LSB- e.g. , using lentiviral vector-mediated gene transfer , which results in persistent transgene expression -LRB- Ruitenberg et al. , 2002 -RRB-	69215
implantation	69215
stable transduced OEG -LSB- e.g. , using lentiviral vector-mediated gene transfer , which results in persistent transgene expression -LRB- Ruitenberg et al. , 2002 -RRB-	69231
stable transduced OEG	69231
e.g. , using lentiviral vector-mediated gene transfer , which results in persistent transgene expression -LRB- Ruitenberg et al. , 2002 -RRB-	69254
lentiviral vector-mediated gene transfer , which results in persistent transgene expression -LRB- Ruitenberg et al. , 2002 -RRB-	69266
lentiviral vector-mediated gene transfer	69266
persistent transgene expression -LRB- Ruitenberg et al. , 2002 -RRB-	69325
persistent transgene expression	69325
Ruitenberg	69358
et al. , 2002	69369
et al.	69369
2002	69377
those implants	69396
grafts of engineered fibroblasts	69423
grafts	69423
engineered fibroblasts	69433
neurotrophin expression	69467
modulation of neurite outgrowth -LRB- Blesch et al. , 2000 , 2001 -RRB-	69520
modulation	69520
neurite outgrowth -LRB- Blesch et al. , 2000 , 2001 -RRB-	69534
neurite outgrowth	69534
Blesch	69553
et al. , 2000 , 2001	69560
et al.	69560
2000	69568
2001	69574
entrapment of axons in areas with high neurotrophic factor expression -LRB- Kirik et al. , 2000 -RRB-	69592
entrapment	69592
axons in areas with high neurotrophic factor expression -LRB- Kirik et al. , 2000 -RRB-	69606
axons	69606
areas with high neurotrophic factor expression -LRB- Kirik et al. , 2000 -RRB-	69615
areas	69615
high neurotrophic factor expression -LRB- Kirik et al. , 2000 -RRB-	69626
high neurotrophic factor expression	69626
Kirik	69663
et al. , 2000	69669
et al.	69669
2000	69677
Sprouting of RST axons	69684
Sprouting	69684
RST axons	69697
the interface of the lesion area and intact spinal cord	69737
the interface	69737
the lesion area and intact spinal cord	69754
the lesion area	69754
intact spinal cord	69774
This	69794
Liu	69820
et al. -LRB- 1999 -RRB-	69824
et al.	69824
1999	69832
the presence of elevated neurotrophin levels	69860
the presence	69860
elevated neurotrophin levels	69876
reactive glia	69906
an attractive area for lesioned axons	69931
an attractive area	69931
lesioned axons	69954
Kawaja and Gage	69978
1991	69995
RST axons	70017
the lesion core that , besides implanted OEG , also contains scar-associated cells -LRB- e.g. , meningeal cells -RRB-	70044
the lesion core	70044
implanted OEG	70074
scar-associated cells -LRB- e.g. , meningeal cells -RRB-	70103
scar-associated cells	70103
e.g. , meningeal cells	70126
e.g.	70126
meningeal cells	70132
Several growth inhibitory molecules	70150
these cells	70212
RST axons	70246
this area	70261
review	70276
Fawcett and Asher , 1999 ; Pasterkamp et al. , 1999 ; De Winter et al. , 2002	70288
Fawcett and Asher , 1999 ; Pasterkamp et al. , 1999 ; De Winter et al.	70288
Fawcett and Asher , 1999	70288
Fawcett and Asher	70288
1999	70307
Pasterkamp et al. , 1999	70313
Pasterkamp	70313
et al. , 1999	70324
et al.	70324
1999	70332
De Winter et al.	70338
De Winter	70338
et al.	70348
2002	70356
Implantation of NT-3-producing OEG	70363
Implantation	70363
NT-3-producing OEG	70379
a growth response of axotomized RST axons	70413
a growth response	70413
axotomized RST axons	70434
the receptors for BDNFand NT-3 , TrkB and TrkC ,	70465
the receptors	70465
BDNFand NT-3 , TrkB and TrkC ,	70483
BDNFand NT-3	70483
TrkB and TrkC	70497
rubrospinal neurons	70531
these neurotrophins	70552
distinct roles	70585
injury	70606
NT-3	70614
injury-induced death	70642
newborn rats -LRB- Diener and Bregman , 1994 -RRB-	70666
newborn rats	70666
Diener and Bregman	70680
1994	70700
contrast to BDNF	70714
contrast	70714
BDNF	70726
regeneration-associated gene expression	70748
lesion-induced atrophy	70799
adulthood -LRB- Kobayashi et al. , 1997 -RRB-	70829
adulthood	70829
Kobayashi	70840
et al. , 1997	70850
et al.	70850
1997	70858
This	70865
a role for NT-3 in survival of RST neurons rather than axonal regeneration , which is opposite for the CST , in which BDNF was shown to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	70879
a role	70879
NT-3 in survival of RST neurons rather than axonal regeneration , which is opposite for the CST , in which BDNF was shown to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	70890
NT-3 in survival of RST neurons	70890
NT-3	70890
survival of RST neurons	70898
survival	70898
RST neurons	70910
axonal regeneration , which is opposite for the CST , in which BDNF was shown to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	70934
axonal regeneration	70934
opposite for the CST , in which BDNF was shown to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	70964
opposite	70964
the CST , in which BDNF was shown to promote survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	70977
the CST	70977
BDNF	70995
survival but not regeneration -LRB- Lu et al. , 2001b -RRB-	71021
survival	71021
regeneration -LRB- Lu et al. , 2001b -RRB-	71038
regeneration	71038
Lu	71052
et al. , 2001b	71055
et al.	71055
2001b	71063
implantation of a peripheral nerve graft	71077
implantation	71077
a peripheral nerve graft	71093
regeneration of RST fibers	71119
regeneration	71119
RST fibers	71135
Richardson et al. , 1984	71165
Richardson	71165
et al.	71176
1984	71184
the fact that Schwann cells appear more potent growth promoters for RST axons	71199
the fact	71199
Schwann cells	71213
more potent growth promoters for RST axons	71234
more potent growth promoters	71234
RST axons	71267
evidence	71278
they	71304
a CNS environment	71335
inhibitory chondroitinsulfate proteoglycan expression in astrocytes -LRB- Plant et al. , 2001 ; Takami et al. , 2002 -RRB-	71368
inhibitory chondroitinsulfate proteoglycan expression	71368
astrocytes -LRB- Plant et al. , 2001 ; Takami et al. , 2002 -RRB-	71425
astrocytes	71425
Plant	71437
et al. , 2001 ; Takami et al. , 2002	71443
et al.	71443
2001 ; Takami et al.	71451
2001	71451
Takami et al.	71457
Takami	71457
et al.	71464
2002	71472
OEG	71490
better candidates as cellular platforms for ex vivo gene transfer to repair the injured spinal cord	71503
better candidates	71503
cellular platforms for ex vivo gene transfer to repair the injured spinal cord	71524
cellular platforms	71524
ex vivo gene transfer to repair the injured spinal cord	71547
ex vivo gene transfer	71547
the injured spinal cord	71579
contrast to genetically modified fibroblasts , OEGare of CNS origin and normally express a subset of factors that support neurite outgrowth -LRB- for review , see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001 -RRB-	71620
contrast	71620
genetically modified fibroblasts , OEGare of CNS origin and normally express a subset of factors that support neurite outgrowth -LRB- for review , see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001 -RRB-	71632
genetically modified fibroblasts	71632
OEGare of CNS origin and normally express a subset of factors that support neurite outgrowth -LRB- for review , see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001 -RRB-	71665
OEGare of CNS origin and normally express a subset of factors that support neurite outgrowth	71665
OEGare	71665
CNS origin and normally express a subset of factors that support neurite outgrowth	71675
CNS origin	71675
a subset of factors that support neurite outgrowth	71707
a subset	71707
factors that support neurite outgrowth	71719
factors	71719
neurite outgrowth	71740
review , see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001	71763
review	71763
see Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001	71771
Ramon-Cueto and Avila , 1998 ; Woodhall et al. , 2001	71775
Ramon-Cueto and Avila , 1998	71775
Ramon-Cueto and Avila	71775
1998	71798
Woodhall et al. , 2001	71804
Woodhall	71804
et al. , 2001	71813
et al.	71813
2001	71821
The combination of neural transplantation and neurotrophin delivery	71828
The combination	71828
neural transplantation and neurotrophin delivery	71847
a promising strategy	71911
regeneration and functional recovery	71943
spinal cord injury	71986
review	72010
Bunge , 2001 ; Blits et al. , 2002	72022
Bunge , 2001	72022
Bunge	72022
2001	72029
Blits et al. , 2002	72035
Blits	72035
et al. , 2002	72041
et al.	72041
2002	72049
We	72056
ex vivo transduction of OEG with BDNF - or NT-3-encoding AdV vectors	72076
ex vivo transduction	72076
OEG with BDNF - or NT-3-encoding AdV vectors	72100
OEG	72100
BDNF - or NT-3-encoding AdV vectors	72109
lesion size	72174
2	72188
the growth-promoting properties of these cells , and -LRB- 3 -RRB- improve functional recovery after implantation	72199
the growth-promoting properties of these cells	72199
the growth-promoting properties	72199
these cells	72234
-LRB- 3 -RRB- improve functional recovery after implantation	72251
improve functional recovery	72255
implantation	72289
A limitation of AdV vector-transduced OEG implants	72303
A limitation	72303
AdV vector-transduced OEG implants	72319
they	72362
robust growth of RST axons	72382
robust growth	72382
RST axons	72399
the injury site , which is essential to restore damaged neural networks	72421
the injury site	72421
damaged neural networks	72468
Stable transduction of OEG with neurotrophin-encoding lentiviral vectors	72493
Stable transduction	72493
OEG with neurotrophin-encoding lentiviral vectors	72516
OEG	72516
neurotrophin-encoding lentiviral vectors	72525
the results obtained , giving hope for the use of these modified cells in both acute and chronic spinal cord injury models	72594
the results obtained	72594
the results	72594
hope for the use of these modified cells in both acute and chronic spinal cord	72623
hope	72623
the use of these modified cells in both acute and chronic spinal cord	72632
the use	72632
these modified cells in both acute and chronic spinal cord	72643
these modified cells	72643
both acute and chronic spinal cord	72667
injury models	72702
